NATIONAL PRISON ENTRANTS' BLOODBORNE VIRUS SURVEY REPORT, 2004.

Prevalence of HIV, hepatitis C, hepatitis B, and risk behaviours among Australian prison entrants.

Centre for Health Research in Criminal Justice (CHRCJ)
& National Centre in HIV Epidemiology and Clinical Research

CHRCJ Research Report No. 1

TONY BUTLER
LENG BOONWAAT
SUE HAILSTONE

NATIONAL PRISON ENTRANTS' BLOODBORNE VIRUS SURVEY

Prevalence of HIV, hepatitis C, hepatitis B, and risk behaviours among Australian prison entrants

NATIONAL REPORT

February 2005

Suggested citation:

Butler T, Boonwaat L, Hailstone S. National Prison Entrants' Bloodborne Virus Survey, 2004. Centre for Health Research in Criminal Justice & National Centre in HIV Epidemiology and Clinical Research, University of New South Wales. 2005. ISBN: 0 7347 37440.

Dedicated to the memory of

Dr. Margaret MacDonald

(1956 – 2003)

CONTENTS

ACKNOWLEDGEMENTS

We wish to thank everyone who assisted in the development and conduct of the National Prison Entrants' Bloodborne Virus Survey including the participants, the health professionals at the survey sites, the prison governors, superintendents, and prison officers for their cooperation in accommodating the survey teams, and the laboratory staff.

The Centre for Health Research in Criminal Justice was formed by Justice Health (formerly Corrections Health Service) in 2003, the culmination of years of support for prisoner health research supported by the Justice Health Board, and specifically the Chair Professor Ron Penny.

We are grateful for the assistance provided by staff at the National Centre in HIV Epidemiology and Clinical Research (NCHECR) - Dr Greg Dore, Professor John Kaldor, Jialan Zhou and Hla-Hla Thein who assisted in adapting the Australian NSP Survey for the prison setting.

This project represents the first national survey of inmate health data and the collaboration of the following state coordinators is appreciated: Leng Boonwaat and Sue Hailstone (New South Wales), Tricia Ginley (Tasmania), Dr Tony Falconer and Pam Lems (Queensland) and Vanessa Read and Dr Ralph Chapman (Western Australia).

The following individuals conducted the interviews:

New South Wales: Robyn Gilmour, Seton Barbour, Leng Boonwaat, Sue Hailstone, Bettina Larsen, Denise Monkley, Michael O'Reilly, Nicky Sharp, Maria Swift and Sandra Travis.

Queensland: Pam Lems and Sandra Wolfenden.

Tasmania: John Cotterill, Tricia Ginley and Karen Glover.

Western Australia: Don Abdullah, Gail Jones, Carolyn Kent, Clive Morrison, Vanessa Read and David Venables.

Financial support:

The NSW component of the project and the central coordination was funded by the AIDS/ Infectious Disease Branch, NSW Health Department. Our thanks go to Kim Stewart, Owen Westcott and Dr Richard Matthews for their ongoing support of prisoner health research.

FOREWORD

The National Prison Entrants' Bloodborne Virus Survey is the first nationally coordinated survey of prisoners conducted in Australia. It represents an important move towards recognising the value of conducting surveillance among marginalised groups. The project is an adjunct to the community Needle and Syringe Program (NSP) survey and will enhance the current national surveillance of bloodborne viruses in high-risk populations.

Monitoring bloodborne virus prevalence among prisoners is important in the response to the spread of bloodborne viruses in Australia. The prevalence of hepatitis C is known to be forty times higher among prisoners than the general community. This project has several unique features: it allows high quality data to be collected on Indigenous Australians entering the criminal justice system, information is collected on non-injectors who may be at risk of bloodborne virus infection, and hepatitis B vaccination status can be examined.

The findings will be used to promote evidence-based policy development in the correctional setting and allow those at risk to be targeted for immunisation and education on harm-minimisation.

Replicating the NSP survey with prison entrants enables comparisons between prisoners with a history of injecting and injecting drug users in the community. The survey also allows information on bloodborne viruses and risk behaviours on other groups including Indigenous Australians. The survey was co-ordinated through the Centre for Health Research in Criminal Justice.

This report presents the findings of the study categorised primarily by injecting status and state.

Professor John Kaldor
Deputy Director
National Centre in HIV Epidemiology and Clinical Research

EXECUTIVE SUMMARY

Background

- Prisoner populations are noted for engaging in high-risk behaviours, particularly injecting drug use in both the community and prison setting. Consequently they are at an increased risk of exposure to bloodborne viruses. Routine screening for bloodborne viruses varies across Australia in terms of both scope and coverage. Following discussions between the Centre for Health Research in Criminal Justice (CHRCJ) and the National Centre in HIV Epidemiology and Clinical Research (NCHECR), it was agreed that the National Needle & Syringe Program survey should be adapted for screening prison entrants.

Methods

- The study was a consecutive cross-section of prison entrants over two weeks in May 2004. Participants were 612 of the 739 consecutive prison entrants in four Australian jurisdictions. Seven sentinel reception centres in New South Wales, Queensland, Tasmania and Western Australia participated in the study.

  The survey screened for the following: HIV antibody and antigen, hepatitis B surface-antibody, hepatitis B core-antibody, hepatitis B surface-antigen, and hepatitis C antibody. Risk factor and demographic information was also collected using a short questionnaire covering injecting drug use, body piercing, tattooing, sexual activity, and immunisation status.

Results

HIV

- Nationally, only three male inmates tested positive for HIV infection; all were previously diagnosed cases.

Hepatitis C (HCV)

- The overall prevalence of hepatitis C was 34% and among injecting drug users, 56%. Hepatitis C prevalence was highest among injecting drug users in NSW (69%) and lowest in Western Australia (33%).

- The prevalence of hepatitis C was 41% among those who had a previous incarceration, and 16% among those entering prison for the first time.

- Hepatitis C prevalence was 54% among men with a history of injecting drug use and 83% among women.

- Similar rates of hepatitis C antibody were found between Indigenous (37%) and non-Indigenous (34%) respondents.

- Thirty six percent of all prison entrants reported never previously being tested for hepatitis C antibody (17% among injecting drug users).

- Twelve percent of the sample were unaware that they were hepatitis C antibody positive prior to screening. This included 6% who reported that they had previously tested negative for hepatitis C.

- One participant reported being previously on interferon treatment for hepatitis C and three participants reported having been on interferon and ribavirin in the past. No respondents reported currently receiving hepatitis C treatment.

Hepatitis B (HBV)

- Similar rates of hepatitis B core antibody prevalence were detected in New South Wales (23%) and Tasmania (26%); lower rates were found in Western Australia (18%) and Queensland (13%).

- Indigenous respondents were more likely than non-Indigenous respondents to have been exposed to hepatitis B (29% *vs.* 18%).

- Among those who reported no previous hepatitis B infection, 37% reported they had never been vaccinated against hepatitis B and 34% reported completing a course of hepatitis B vaccination.

- Nationally, the prevalence of immunity from vaccination against hepatitis B was 25%. This ranged from 17% in New South Wales to 37% in Queensland.

- Injecting drug users were more likely to test positive for hepatitis B than non-injectors (27% *vs.* 9%). Nationally, the hepatitis B carrier rate was 2%.

Substance Use

- Fifty nine percent of prison entrants screened had a history of injecting drugs; 38% had injected in the month prior to reception into prison.

- Amphetamine was the most frequently reported drug last injected across all the states except New South Wales, where heroin was most frequently reported.

- Fifteen percent of those who had injected in the previous month had re-used someone else's needle and syringe.

- Twenty-seven percent of those who had injected in the previous month had re-used someone else's injecting equipment during this period (spoon, water, filter, tourniquet, or drug solution mix).

- It is important that injecting drug users are made aware of the risks of contracting bloodborne viruses through sharing injecting equipment (spoons, water, tourniquet, and the drug mix).

Risk Behaviours

- Sixty nine percent of injecting drug users had used a new needle and syringe for all injections in the month prior to interview.

- Participants who reported sex with only casual partners, were more likely to report using condoms than those with only a single regular sexual partner.

- The proportion of prison entrants who reported having been tattooed by a prison inmate ranged from 14% in Tasmania to 23% in New South Wales.

Implications of the Findings

- Twelve percent of the sample were unaware that they were hepatitis C antibody positive prior to the survey indicating that prison provides an opportunity to screen individuals from high-risk population groups and initiate prevention and treatment measures.

- In order to establish trends in bloodborne virus prevalence among prison entrants the survey should be conducted annually across all jurisdictions. A national approach to bloodborne virus surveillance would be beneficial

- Prevention initiatives should target prison entrants with a history of injecting drugs who are in prison for the first time, this group were less likely to have been exposed to hepatitis C.

- The survey found that 38% of prison entrants reported they had never received a hepatitis B vaccination. Further research is required into effective strategies for promoting vaccination uptake in community and prison settings. Alternative vaccination schedules to increase uptake and completion rates could also be explored. A recent Danish study reported that hepatitis B vaccination in prison with a three-week schedule was more efficient than the standard six-month schedule.[1]

- While, the prevalence of HIV is low across all states, this survey is important in monitoring this trend in a high-risk group and there has been an increase in the numbers of known HIV positive inmates in custody, particularly in New South Wales.

- Only 2% of non-Indigenous participants and none of the Indigenous participants had received treatment for hepatitis C. This suggests that there is a need for increased funding for hepatitis C treatment services in prison and a need to develop culturally appropriate services to ensure Indigenous people have access to these services.

- With amphetamine being the most frequently reported drug last injected by prison entrants, amphetamine substitution therapies should be investigated. Service providers should also ensure staff are trained in recognising and managing amphetamine withdrawal.

- Introducing safe tattooing practices into prisons should be considered.

- This survey demonstrates that further research into injecting drug use in prisons is required. Such data would allow custodial authorities to make informed decisions about the need for greater enforcement or better harm minimisation provision in the custodial setting.

INTRODUCTION

Prisoner populations are associated with engaging in high risk behaviours, particularly injecting drug use.[2 3] Consequently they are at an increased risk of exposure to bloodborne viruses such as hepatitis C, hepatitis B and HIV.[4-8] Studies have also shown that the correctional environment is a high risk environment for bloodborne virus transmission.[7;9;10]

Monitoring bloodborne virus infections occurs through ad hoc prevalence surveys of prisoners conducted in New South Wales and Victoria, and from routine screening of prison receptions undertaken by the states and territories.[5;6;11]

Routine screening practices vary across Australia in terms of both scope and coverage. The Northern Territory and Tasmania have compulsory HIV testing for prisoners, Queensland, South Australia, and Western Australia have voluntary screening, and New South Wales has a targeted approach. HIV screening coverage also varies across the states. In 2002, Queensland and the Northern Territory screened 100% of all men for HIV, Tasmania screened 31%, Western Australia screened 41% and New South Wales screened 28%.[8]

Since 1995, the National Centre in HIV Epidemiology and Clinical Research (NCHECR) has monitored bloodborne viruses in high-risk groups in Australia.[12] Injecting drug users at community Needle and Syringe Programs (NSP) are invited to self-complete a risk behaviour questionnaire and to provide a finger-prick sample of blood to test for HIV and hepatitis C. The survey is conducted annually over a one-week period.

Following discussions between the CHRCJ and the NCHECR, it was agreed to adapt the NSP survey and apply it to the prison setting in an effort to provide systematic information on bloodborne virus prevalence across Australia and to enable comparisons with NSP survey data.

METHODS

Study Sample

The study was a consecutive cross-section of prison entrants over two weeks in May 2004. Participants were 612 of the 739 (83%) consecutive prison entrants in four Australian jurisdictions.

Sample Selection

All new receptions at seven sentinel sites were invited to participate in the assessment. New receptions were defined as individuals entering prison from the community and did not include remanded inmates returning from court appearances or prisoners in transit through the survey site to other prisons.

In New South Wales, potential participants were invited by the research nurses to participate in the survey at the same time that their health and welfare assessments were conducted. Disruption to the prison reception process was minimised by conducting the survey immediately after the health assessment or while the inmate was waiting to be seen by the reception nurse or welfare worker. In Western Australia, all entrants to prison were called up within twenty-four hours of entry. In other states, prison entrants who were not seen at entry were followed up the next day.

Recruitment

Participants were invited into the recruitment area and given an outline of the project by a member of the survey team. The explanation emphasised the following: involvement was voluntary, the structure of the assessment consisted of a short questionnaire followed by blood testing, there was no obligation to answer any questions deemed intrusive or sensitive, and information would remain confidential. Participants were also informed that every effort would be made to return the blood test results and that post-test counselling would be provided and referral made to specialist services if necessary. Signed consent was obtained from all participants.

Confidentiality was maintained on the questionnaires and serology requests through the use of a code comprising the first two letters of each participant's surname and first name, their date of birth and inmate identifier number.

Survey Sites

Seven sentinel reception centres in New South Wales, Queensland, Tasmania and Western Australia participated in the study. These centres receive both male and/or female entrants. Table 1 shows the proportion of all receptions by sex within each state. For example, MRRC in Sydney accepts 68% of all men entering the NSW correctional system.

Table 1: Reception centres and inmate profile.

State	Reception Site	Sex of prison entrants	Percentage of total prison entrants received by each prison within each state
NSW	Metropolitan Reception & Remand Centre (MRRC)	Men	68%
	Mulawa	Women	100%
QLD	Arthur Gorrie	Men	61%
TAS	Hobart Remand	Men and women*	50%
WA	Hakea	Men	63%
	Bandyup	Women	72%
	Roebourne	Men and women*	6%

* Centre receives both men and women prisoners.

Screening Procedures

Screening was divided into several stages to provide a consistent structure to the survey. Broadly, this involved recruiting participants and obtaining consent, administering the questionnaire, providing pre-test counselling for those who consented to blood testing, and collecting the blood specimen. Pre-test discussion included psychological assessment of the inmate's ability to deal with a positive result, provision of information about the possible consequences of infection with bloodborne viruses, transmission risks, confidentiality and notification requirements related to blood tests and treatment options for those who tested positive. Those who consented to the blood test were also informed that face-to-face post-test counselling would be provided as soon as results became available for both positive and negative test results.

Blood Testing

Screening for bloodborne viruses included the following:

- HIV antibody and antigen
- Hepatitis B surface-antibody
- Hepatitis B (IgM & IgG) core-antibody
- Hepatitis B surface-antigen, and if positive hepatitis B e-antigen and e-antibody
- Hepatitis C antibody

Details of test kits used and testing centres are given in Appendices 1 & 2.

Questionnaire

The NSP survey questionnaire was originally designed for the community setting and collects risk factor information on body piercing, tattooing, injecting drug use, sexual activity, and immunisation status. A small number of modifications were made to this screening instrument to adapt it to the correctional setting (Appendix 3). The questionnaire was piloted in each jurisdiction to ensure it was appropriate.

Statistical Analysis

All data was analysed using SPSS version 11.5. Associations between demographic and behavioural variables and syringe use were assessed using the χ^2 test.

Interviewers

Interviewers were recruited from nursing staff within each state's correctional health system. All interviewers were briefed regarding the administration of the questionnaire. Three Aboriginal health workers were recruited in Western Australia to facilitate data collection among the Indigenous prisoners. Several telephone conferences were also held as a means of ensuring consistency in approach.

Ethics Approval

The primary ethics committees for the project were the New South Wales Justice Health, Human Research & Ethics Committee, the University of New South Wales Ethics Committee, and the Aboriginal Health and Medical Research Council (AHMRC). Ethics approval was also sought from each state's Department of Justice or Corrective Services' research committee.

For Western Australia, the survey also received endorsement from the Aboriginal Community Controlled Health Organisation.

Reporting of Results

The following sections present the findings from the survey stratified primarily by injecting drug use. Percentages have been rounded to the nearest whole number. In this report, the words prison entrant and inmate are used interchangeably as are reception centre and prison.

RESULTS

Response Rate

A number of inmates declined to participate in the survey. Some inmates agreed to answer the questionnaire but opted not to provide blood. A few others agreed to provide a blood sample but were unable to do so because of the condition of their veins. A small number agreed to blood testing but declined the questionnaire (Table 2). Some of the reasons cited by the refusers included a perceived lack of personal gain from participation, needle phobia, and feeling fatigued or stressed during the reception process.

The response rate was calculated as follows:

$$\frac{\textit{Total participants}}{\textit{Total receptions}} \; X\,100$$

The overall response rate was 77% for the questionnaire and 63% for serology. Men were more likely than women to agree to participate in the survey. The questionnaire response rate was 83% for men and 73% for women. Furthermore, 66% of men compared with 42% of women provided blood for serological testing. Similar proportions of Indigenous and non-Indigenous prison entrants responded to the questionnaire (88% Indigenous *vs*. 86% non-Indigenous). Blood was provided for serological testing by 70% of Indigenous prison entrants compared to 65% of non-Indigenous prison entrants.

Prison entrants from seven reception centres across four states participated in the study. The rate of screening ranged from 57% at Hobart Remand to 100% at Roebourne, a remote and predominantly Indigenous prison in Western Australia (Table 2).

Table 2: Reception centre, sex, participants screened and total number of receptions.

State	Reception Centre	Sex	Nº of receptions	Nº screened* (%)
NSW	Metropolitan Reception and Remand Centre	Men	304	272 (89)
	Mulawa	Women	55	39 (71)
QLD	Arthur Gorrie	Men	157	140 (89)
TAS	Hobart Remand & Risdon	Men	65	38 (58)
		Women	11	6 (55)
		Not reported	1	0 (0)
WA	Hakea	Men	104	79 (76)
	Bandyup	Women	27	23 (85)
	Roebourne	Men	12	12 (100)
		Women	3	3 (100)
Total			739	612 (83)

* Completed questionnaire and/or serological testing

A total of 604 prison entrants agreed to participate in the questionnaire. Reporting is stratified by injecting drug use. Over half (59%) of the questionnaire respondents reported current or previous injecting drug use (Table 3).

Table 3: Structure of the study sample*

	Ever Inject Drugs		
Sex	**No**	**Yes**	**Total**
Men	228 (43)	307 (57)	535 (100)
Women	19 (28)	49 (72)	68 (100)
Transgender	0 (0)	1 (100)	1 (100)
Total	247 (41)	357 (59)	604 (100)

* Based on responses to questionnaire

Table 4: Demographic characteristics of prison entrants by state

	NSW	QLD	TAS	WA	Total
Nº surveyed	311	140	44	112	607
Nº of sites	2	1	2	3	7
Median age	31	31	30	30	31
Age range	18-75	17-64	17-64	18-60	17-75
Nº (%) Indigenous	37 (12)	14 (10)	6 (14)	45 (39)	102 (17)
Nº (%) Male	271 (87)	140 (100)	38 (86)	93 (80)	542 (89)
Nº (%) Australian born	244 (79)	111 (79)	44 (100)	99 (88)	493 (82)

Table 5: Demographic characteristics of drug injecting prison entrants by state

	NSW	QLD	TAS	WA	Total
Nº surveyed	183	82	26	66	357
Median age	30	29	30	30	31
Age range	18-58	17-53	20-48	18-47	17-58
Nº (%) Indigenous	28 (15)	8 (10)	2 (8)	26 (39)	64 (18)
Nº (%) Male	152 (83)	82 (100)	22 (85)	51 (77)	307 (87)
Nº (%) Australian born	156 (85)	71 (87)	26 (100)	57 (88)	310 (87)

Table 6: Injecting drug use by state

	NSW	QLD	TAS	WA	Total
Nº (%) with history of IDU	184 (59)	82 (58)	26 (63)	66 (58)	358 (59)
Nº (%) injected in the last month					
Did not inject in the last month	55 (30)	32 (39)	12 (46)	24 (38)	123 (35)
Yes, injected in the last month	128 (69)	50 (61)	14 (54)	40 (62)	232 (65)
Not reported	1 (<1)	0 (0)	0 (0)	2 (3)	3 (<1)
Last drug injected	N = 184	N = 82	N = 26	N = 66	N = 358
Amphetamine	72 (39)	59 (72)	17 (65)	53 (80)	201 (56)
Heroin	84 (46)	20 (24)	2 (8)	4 (6)	110 (31)
Morphine	1 (<1)	2 (1)	3 (4)	3 (2)	9 (3)
Cocaine	7 (4)	---	---	---	7 (2)
More than one	7 (4)	---	3 (12)	4 (6)	14 (4)
Other/not reported	21 (11)	3 (4)	4 (15)	5 (8)	33 (9)
Places injected last month	N =128	N = 50	N = 14	N = 40	N = 232
Prison	3 (2)	3 (6)	1 (7)	1 (3)	8 (3)
Own home	99 (77)	45 (90)	11 (79)	26 (70)	181 (78)
Friend's home	54 (43)	37 (74)	7 (50)	19 (51)	117 (50)
Dealer's home	21 (17)	23 (46)	2 (14)	5 (14)	5 (2)
Street, park	40 (32)	25 (50)	2 (14)	6 (16)	73 (31)
Car	37 (29)	31 (62)	7 (50)	7 (19)	82 (35)
Public toilet	29 (23)	21 (42)	4 (29)	2 (5)	56 (24)
Medically supervised injecting centre	5 (4)	4 (8)	---	---	9 (4)
Used new fit for all injections in the last month	N =128	N = 50	N = 14	N = 40	N = 232
Yes	86 (67)	37 (74)	12 (86)	25 (63)	160 (69)
No	42 (33)	13 (26)	2 (14)	14 (35)	72 (31)
Not reported	1 (<1)	---	---	1 (2)	2 (<1)
Frequency fits obtained from NSP last month	N =184	N = 82	N = 26	N = 66	N = 358
Daily or almost daily	17 (9)	11 (13)	2 (8)	3 (5)	31 (9)
A couple of times per week	21(11)	10 (12)	2 (8)	5 (8)	38 (11)
Less than weekly	14 (8)	8 (10)	4 (15)	7 (11)	33 (9)
Once last month	24 (13)	10 (12)	---	5 (8)	39 (11)
Not in the last month	28 (15)	11 (13)	4 (15)	18 (27)	57 (16)
Not reported	25 (14)	---	2 (8)	2 (3)	34 (9)
Frequency fits obtained from chemist last month	N =184	N = 82	N = 26	N = 66	N = 358
Daily or almost daily	5 (3)	4 (5)	2 (8)	6 (9)	17 (5)
A couple of times per week	17 (9)	12 (15)	1 (4)	6 (9)	36 (10)
Less than weekly	30 (16)	12 (15)	1 (4)	8 (12)	51 (14)
Once last month	19 (10)	7 (18)	6 (23)	6 (9)	38 (11)
Not in the last month	54 (29)	15 (18)	4 (15)	13 (19)	86 (24)
Not reported	4 (2)	---	---	1 (2)	4 (1)

Table 7: HIV prevalence by state

	NSW		QLD		TAS		WA		Total*	
	Nº tested	Nº with HIV	Nº tested	Nº with HIV	Nº tested	Nº with HIV	Nº tested	Nº with HIV	Nº tested	Nº with HIV
Non- injector										
Male	75	0 (0)	53	1 (2)	8	2 (1)	36	0 (0)	172	1 (1)
Female	5	0 (0)	---	---	---	---	7	0 (0)	12	0 (0)
Injector										
Male	104	2 (2)	77	0 (0)	15	0 (0)	43	0 (0)	239	2 (1)
Female	16	0 (0)	---	---	2	0 (0)	5	0 (0)	23	0 (0)
Total	120	2 (2)	130	1 (1)	25	0 (0)	91	0 (0)	*446	3 (1)

*Total excludes transgender-identified participants

Table 8: HCV prevalence by state

	NSW		QLD		TAS		WA		Total*	
	Nº tested	Nº with HCV	Nº tested	Nº with HCV	Nº tested	Nº with HCV	Nº tested	Nº with HCV	Nº tested	Nº with HCV
Non- injector										
Male	75	2 (3)	54	2 (4)	9	1 (11)	36	2 (6)	174	7 (4)
Female	5	0 (0)	---	---	---	---	7	0 (0)	12	0 (0)
Injector										
Male	108	72 (67)	74	36 (48)	16	10 (63)	43	12 (28)	242	130 (54)
Female	16	13 (81)	---	---	2	2 (100)	5	4 (80)	23	19 (83)
Total	204	87 (43)	128	38 (30)	27	13 (48)	91	18 (20)	*451	156 (35)

*Total excludes transgender-identified participants

Table 9: HBV core antibody prevalence by state

	NSW		QLD		TAS		WA		Total	
	Nº tested	Nº with HBV(%)	Nº tested	Nº with HBV(%)	Nº tested	Nº with HBV(%)	Nº tested	Nº with HBV(%)	Nº tested	Nº with HBV(%)
Non- injector										
Male	75	6 (8)	54	5 (9)	9	0 (0)	35	3 (9)	173	14 (8)
Female	5	2 (60)	---	---	---	---	5	0 (0)	5	2 (40)
Injector										
Male	107	35 (33)	74	12 (16)	16	6 (38)	44	11 (25)	241	64 (27)
Female	16	3 (19)	---	---	3	2 (67)	4	2 (50)	23	7 (30)
Total	203	46 (23)	128	17 (13)	28	8 (28)	88	16 (18)	442	87 (20)

Table 10: HBV surface antigen prevalence by state

	NSW		QLD		TAS		WA		Total	
	Nº tested	Nº with HBV(%)	Nº tested	Nº with HBV(%)	Nº tested	Nº with HBV(%)	Nº tested	Nº with HBV(%)	Nº tested	Nº with HBV(%)
Non- injector										
Male	75	0 (0)	54	0 (0)	8	0 (0)	35	0 (0)	172	0 (0)
Female	5	0 (0)	---	---	---	---	7	0 (0)	12	0 (0)
Injector										
Male	108	6 (6)	77	3 (4)	15	0 (0)	44	3 (7)	244	12 (5)
Female	16	0 (0)	---	---	3	1 (33)	5	0 (0)	24	1 (4)
Total	204	6 (3)	131	3 (4)	26	1 (4)	91	3 (3)	452	13 (3)

Table 11: Prevalence of serological markers of HBV immunity* from vaccination by state

	NSW		QLD		TAS		WA		Total	
	Nº tested	Nº immune(%)	Nº tested	Nº immune(%)	Nº tested	Nº immune(%)	Nº tested	Nº immune(%)	Nº tested	Nº immune (%)
Non- injector										
Male	68	8 (12)	43	14 (33)	9	1 (11)	32	8 (25)	152	31 (20)
Female	2	1 (50)	5	1 (20)	---	---	---	---	7	2 (29)
Injector										
Male	70	19 (27)	56	32 (57)	10	4 (40)	33	13 (39)	169	68 (40)
Female	13	5 (39)	---	---	1	0 (0)	2	1 (50)	16	6 (38)
Total	153	33 (22)	104	47 (45)	20	5 (25)	67	22 (33)	344	107 (31)

*Surface antibody levels of $\geq$10 are considered immune. Those with serological markers of immunity from previous HBV infection have been excluded.

Table 12: Self reported hepatitis B immunisation versus serology results

	Serological markers of immunity*									
	NSW		QLD		TAS		WA		Total	
	Nº tested	Nº immune (%)	Nº tested	Nº immune (%)	Nº tested	Nº immune (%)	Nº tested	Nº immune (%)	Nº tested	Nº immune (%)
Nil vaccinations received	59	6 (10)	27	4 (15)	9	0 (0)	36	7 (19)	131	17 (13)
One vaccination	7	2 (29)	6	1 (17)	---	---	2	0 (0)	15	3 (20)
Two vaccinations	11	3 (27)	5	2 (40)	2	0 (0)	9	5 (56)	27	10 (37)
Three or more vaccinations	38	18 (47)	61	39 (63)	8	5 (63)	11	5 (46)	118	68 (58)
Unsure or not reported	38	4 (10)	---	---	1	0 (0)	14	9 (65)	53	9 (17)
Total	153	33 (22)	99	46 (47)	20	5 (25)	72	49 (68)	344	107 (31)

*Surface antibody levels of ≥10 are considered immune. Those with serological markers of a previous HBV infection have been excluded.

Table 13: Self reported previous hepatitis C test result versus serology results

	Serology results									
	NSW		QLD		TAS		WA		Total	
	Nº tested	Nº HCV +ve (%)	Nº tested	Nº HCV +ve (%)	Nº tested	Nº HCV +ve (%)	Nº tested	Nº HCV +ve (%)	Nº tested	Nº immune (%)
Previously tested negative	49	13 (27)	61	5 (8)	7	2 (29)	28	6 (21)	145	26 (18)
Previously tested positive	57	56 (98)	29	29 (100)	10	10 (100	8	8 (100)	104	103 (99)
Don't know	15	9 (60)	4	2 (50)	2	1 (50)	3	2 (67)	24	14 (58)
Never tested	82	9 (11)	35	2 (6)	8	0 (0)	51	2 (4)	176	13 (7)
Not reported	1	0 (0)	---	---	---	---	---	---	1	0 (0)
Total	204	87 (43)	129	38 (29)	27	13 (48)	90	18 (20)	450	156 (35)

Table 14: Types of sexual partner in the past month and condom use during last episode of sexual activity by state

	NSW		QLD		TAS		WA		Total	
	Nº surveyed	Nº used condoms (%)	Nº surveyed	Nº used condoms (%)	Nº surveyed	Nº used condoms (%)	Nº surveyed	Nº used condoms (%)	Nº surveyed	Nº used condoms (%)
Regular partner only	153	21 (14)	75	7 (9)	16	3 (19)	48	10 (21)	292	41 (14)
Casual partner only	46	23 (50)	24	15 (63)	6	1 (17)	11	4 (36)	87	43 (49)
Regular and casual partners	24	9 (38)	13	12 (92)	2	0 (0)	14	3 (21)	53	14 (26)
No sexual partners last month*	88	---	28	---	17	---	40	---	173	---

*Or not reported

Table 15: Type of sexual partner within the last month and condom use, by state

	NSW		QLD		TAS		WA		Total	
Nº surveyed	Nº always used condoms (%)	Nº surveyed	Nº always used condoms (%)	Nº surveyed	Nº always used condoms (%)	Nº surveyed	Nº always used condoms (%)	Nº surveyed	Nº always used condoms (%)	Nº surveyed
Regular sexual partner										
170	14 (8)	86	5 (6)	17	2 (12)	53	6 (11)	326	27 (8)	1153
Casual sexual partner										
63	25 (40)	29	4 (48)	7	0 (0)	22	3 (14)	121	42 (35)	698
New sexual partner										
31	16 (52)	10	0 (0)	2	0 (0)	25	5 (20)	68	21 (31)	759

*Unreported data has been excluded.

Table 16: Prison entrants who reported ever having a tattoo, by state

	NSW		QLD		TAS		WA		Total	
	Nº surveyed	Nº with tattoos (%)	Nº surveyed	Nº with tattoos (%)	Nº surveyed	Nº with tattoos (%)	Nº surveyed	Nº with tattoos (%)	Nº surveyed	Nº with tattoos (%)
Non- injector										
Male	117	57 (49)	58	28 (48)	14	6 (43)	38	12 (32)	227	103 (45)
Female	9	2 (22)	---	---	1	0 (0)	9	4 (44)	19	6 (32)
Injector										
Male	152	111 (73)	82	59 (72)	22	20 (91)	51	32 (63)	307	222 (72)
Female	30	23 (77)	---	---	4	4 (100)	15	11 (73)	49	38 (78)
Total	308	193 (63)	140	87 (62)	41	30 (73)	113	59 (52)	602	369 (61)

Table 17: Type of person tattoo was provided by, if tattooed within the last year, by state

	NSW	QLD	TAS	WA	Total
Nº tattooed within the last year:	31	19	7	12	69
Nº (%) who received tattoos provided by:					
Parlour or professional tattooist	18 (58)	11 (58)	4 (57)	9 (75)	42 (61)
Friend	6 (19)	2 (11)	1 (14)	4 (33)	13 (19)
Prison inmate	7 (23)	3 (16)	1 (14)	2 (17)	13 (19)
Self	4 (13)	3 (16)	1 (14)	1 (8)	9 (13)
Family member	1 (3)	1 (5)	---	---	2 (3)

Table 18: Prison entrants who reported ever being pierced by state

	NSW		QLD		TAS		WA		Total	
	Nº surveyed	Nº with piercing (%)	Nº surveyed	Nº with piercing (%)	Nº surveyed	Nº with piercing (%)	Nº surveyed	Nº with piercing (%)	Nº surveyed	Nº with piercing (%)
Non- injector										
Male	117	36 (31)	58	18 (31)	14	6 (43)	38	13 (34)	227	73 (32)
Female	9	6 (67)	---	---	1	1 (100)	9	5 (56)	19	12 (63)
Injector										
Male	152	66 (43)	81	31 (38)	22	11 (50)	51	25 (49)	306	133 (43)
Female	30	23 (77)	---	---	4	4 (100)	15	11 (73)	49	38 (78)
Total	308	131 (43)	139	49 (35)	41	22 (54)	113	34 (30)	601	256 (43)

Table 19: Type of person piercing was provided by if pierced within the last year, by state

	NSW	QLD	TAS	WA	Total
Nº pierced within the last year:	14	5	1	8	28
Nº (%) who received tattoos provided by:					
Professional piercer/ studio	8 (57)	1 (20)	1 (100)	3 (38)	13 (46)
Tattooist parlour	---	---	---	3 (38)	3 (11)
Friend	---	1 (20)	---	1 (13)	2 (7)
Prison inmate	---	1 (20)	---	---	1 (4)
Self	1 (7)	3 (60)	---	1 (13)	5 (18)
Family member	---	---	---	---	---

Table 20: Number (%) of respondents by demographic characteristics and sex by injector status

Demographic characteristics	Non-injector	Injector	Total
N° surveyed	N = 247	N = 357	N = 604*
Sex (%)			
Male	228 (92)	307 (86)	535 (89)
Female	19 (8)	49 (14)	68 (11)
Transgender	---	1 (<1)	1 (<1)
Sexual identity (%)			
Heterosexual	240 (97)	341 (96)	581 (96)
Bisexual	3 (1)	11 (3)	14 (2)
Homosexual	3 (1)	5 (<1)	8 (1)
Not reported	1 (<1)	---	1 (<1)
Age and duration of injection (years)			
Median age	34	30	31
Age range	17 - 75	17 - 58	17 - 75
Age group (%)			
<25 years	69 (28)	95 (27)	164 (27)
25+ years	178 (72)	257 (72)	435 (73)
Not reported	---	5 (1)	5 (<1)
Median age 1st IDU	---	18	18
Age range	---	9 – 41	---
Median years IDU	---	10	---
Range	---	<1 – 37	---
Duration of drug injection (%)			
<3 years	---	36 (10)	36 (6)
3+ years	---	311 (87)	311 (51)
Not reported	---	10 (3)	10 (2)
Aboriginal and Torres Strait Islander origin (%)			
No	209 (85)	285 (80)	494 (82)
Yes	36 (15)	64 (18)	100 (17)
Not reported	2 (<1)	8 (2)	10 (2)
Region / Country of birth (%)			
Australia	182 (74)	310 (87)	492 (82)
Other Oceania	17 (7)	12 (3)	29 (5)
Asia	14 (6)	13 (4)	27 (4)
UK & Ireland	9 (4)	8 (2)	17 (3)
Other	23 (9)	13 (4)	36 (6)
Not reported	2 (<1)	1 (<1)	2 (<1)
Main language spoken at home by parents (%)			
English speaking	208 (84)	328 (92)	536 (89)
Non-English speaking	37 (15)	28 (8)	65 (11)
Not reported	2 (1)	1 (<1)	3 (<1)
Imprisonment last year (%)			
No	135 (55)	128 (36)	263 (44)
Yes	100 (40)	221 (62)	321 (53)
Not reported	12 (5)	8 (2)	20 (3)
Injected in prison last month (%)		N = 232	N = 232
Yes	---	8 (2)	8 (1)
No	---	349 (98)	596 (99)
Frequency of injection last month (%)		N = 232	N = 232
Not last month	---	125 (35)	125 (21)
Less than weekly	---	47 (13)	47 (8)
Weekly not daily	---	28 (8)	28 (5)
Daily or more	---	154 (43)	154 (25)
Not reported	---	3 (<1)	3 (<1)

*Total excludes prison entrants who did not disclose injector status

NATIONAL

Table 21: Number (%) of respondents by last drug injected and injecting behaviour in the month prior to survey

Injecting Behaviour

Last drug injected (%)	**N = 357**	
Amphetamine	206	(58)
Anabolic steroids	1	(<1)
Cocaine	7	(2)
Heroin	115	(32)
Heroin + Cocaine	2	(1)
Methadone	7	(2)
Morphine	9	(3)
Other	10	(3)
Places injected last month (%)**	**N= 232**	
Prison	8	(3)
Own home	181	(78)
Friend's home	117	(50)
Dealer's home	51	(22)
Street, park, beach	73	(31)
Car	82	(35)
Public toilet	56	(24)
Shooting room	8	(3)
MSIC*	9	(4)
Squat	19	(8)
Train, bus or cab	5	(2)
Not reported	6	(3)
Use of new sterile needles & syringes last month (%)		
All injections	160	(69)
Most of the time	38	(16)
Half of the time	14	(6)
Some of the time	17	(7)
Not last month	2	(1)
Not reported	1	(<1)

*Medically Supervised Injecting Centre

Re-used someone else's needle & syringe last month (%)		
None	196	(84)
Once	6	(3)
Twice	14	(6)
3 - 5 times	7	(3)
More than five	7	(3)
Not reported	2	(1)
Number of people needle & syringe was re-used after last month (%)		
None	197	(85)
One	20	(9)
Two	7	(3)
Three to five	4	(2)
More than five	2	(<1)
Not reported	2	(<1)
Relationship to people needle & syringe was re-used after last month (%)**		
Regular sex partner	18	(8)
Casual sex partner	2	(1)
Close friend	7	(3)
Acquaintance	5	(2)
Stranger	1	(<1)
Family	2	(1)
Brother	1	(<1)
Other/ not specified	1	(<1)
Equipment used after someone else last month (%)**		
None	213	(92)
Spoon	49	(21)
Water	39	(17)
Filter	34	(15)
Tourniquet	18	(8)
Drug mix	33	(14)
Injected by someone after that person injected themselves or others last month (%)		
No	202	(87)
Yes	26	(11)
Not reported	4	(2)

**More than one option could be selected

Table 22: Number (%) of respondents by treatment for drug use and injector status

	Non-injector		Injector		Total	
Nº Surveyed	N = 247		N = 357		N = 604	
Any treatment/therapy for drug use (%)						
No	228	(92)	195	(55)	423	(70)
Yes	17	(7)	161	(45)	178	(29)
Not reported	2	(<1)	1	(<1)	3	(<1)
History of methadone treatment (%)						
Currently	3	(1)	53	(15)	56	(9)
Previously	2	(1)	76	(21)	78	(13)
Never	240	(97)	226	(63)	466	(77)
Not reported	2	(1)	2	(1)	4	(1)
History of other pharmacotherapy treatment (%)						
Currently	3	(1)	19	(5)	22	(4)
Previously	1	(>1)	49	(14)	50	(8)
Never	241	(98)	284	(80)	525	(87)
Not reported	2	(1)	5	(1)	7	(1)

Table 23: Number (%) of respondents by site of needle and syringe acquisition last month

Needle and syringe acquisition		
Nº surveyed	N = 232	
From an NSP last month (%)		
Daily or almost daily	31	(13)
A couple of times each week	38	(16)
Less than weekly	33	(14)
Once last month	39	(17)
Not in the last month	57	(25)
Not reported	34	(15)
From a chemist last month (%)		
Daily or almost daily	17	(7)
A couple of times each week	36	(16)
Less than weekly	51	(22)
Once last month	38	(16)
Not in the last month	86	(37)
Not reported	4	(1)

Table 24: Number (%) of respondents by sexual behaviour in the month prior to survey and injector status

Sexual Behaviour	Non-injector		Injector		Total	
Nº surveyed	N = 247		N = 357		N = 604	
Sex last month (%)						
No	75	(30)	93	(26)	168	(28)
Yes	168	(68)	263	(74)	431	(71)
Not reported	4	(2)	1	(<1)	5	(1)
Condom use at last sex (%)						
No	175	(71)	270	(76)	445	(74)
Yes	69	(28)	87	(24)	156	(26)
Not reported	3	(1)		---	3	(<1)
Condom use with regular sex partner(s) last month (%)*						
No	112	(81)	160	(86)	272	(84)
Sometimes	12	(9)	14	(7)	26	(8)
Always	14	(10)	13	(7)	27	(8)
Condom use with new sex partner(s) last month (%)*						
No	9	(47)	27	(55)	36	(53)
Sometimes	3	(16)	8	(16)	11	(16)
Always	7	(37)	14	(29)	21	(31)
Condom use with casual sex partner(s) last month (%)*						
No	18	(47)	41	(49)	59	(49)
Sometimes	6	(16)	14	(17)	20	(17)
Always	14	(37)	28	(34)	42	(35)
Duration of regular sexual relationship (%)*						
One month		---	3	(1)	3	(1)
2 - 6 months	8	(5)	10	(5)	18	(5)
6 - 12 months	16	(11)	10	(5)	26	(7)
> 12 months	80	(54)	104	(51)	184	(52)
Not reported	43	(29)	77	(38)	120	(34)
Sex work last month (%)**						
No	240	(97)	349	(98)	589	(98)
Yes	2	(1)	6	(2)	8	(1)
Not reported	5	(2)	2	(<1)	7	(1)
Condom used at last sex work last month (%)**						
No	1	(50)	2	(33)	3	(38)
Yes	1	(50)	3	(50)	4	(50)
Not reported			1	(17)	1	(12)

* Percentages exclude missing data and participants reporting no regular, new or casual sex partners respectively in the previous month

** Percentages exclude missing data

Table 25: Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, hepatitis B vaccination and treatment for HCV by injector status

	Non-injector	Injector	Total
N° surveyed	N = 247	N = 357	N = 604
Previous HIV test (%)			
Yes, last year	46 (19)	168 (47)	214 (35)
> 1 year ago	72 (29)	117 (33)	189 (31)
Never tested	126 (51)	71 (20)	197 (33)
Not reported	3 (1)	1 (<1)	4 (<1)
HBV infection (%)			
No	226 (91)	278 (78)	504 (83)
Yes	5 (2)	51 (14)	56 (9)
Don't know	16 (6)	28 (8)	44 (7)
Hepatitis B vaccination (%)*	N = 242	N = 306	N = 548
No	116 (48)	82 (26)	198 (36)
Yes	78 (33)	188 (64)	266 (48)
Don't know	44 (18)	36 (12)	80 (15)
Not reported	4 (2)	---	4 (<1)
Previous HCV test (%)			
Yes, last year	42 (17)	155 (43)	197 (33)
> 1 year ago	48 (20)	138 (39)	186 (31)
Never tested	154 (63)	61 (17)	215 (36)
Not reported	3 (<1)	3 (<1)	6 (<1)
Any treatment for HCV (%)**	N = 2	N = 156	N = 158
Interferon	---	1 (<1)	1 (<1)
Interferon & Ribavirin	1 (50)	2 (1)	3 (2)
Pegasys & Ribavirin	---	---	---
Other	---	---	---
No treatment	1 (50)	153 (98)	154 (98)
Current treatment for HCV			
Interferon	---	---	---
Interferon & Ribavirin	---	---	---
Other	---	---	---

*Participants who self-reported a previous HBV infection have been excluded.

**Participants who did not self-report being HCV antibody positive have been excluded.

Table 26: HIV antibody prevalence by sex and injector status

	Male		Female		Total	
Injector status	**N° tested**	**N° with HIV (%)**	**N° tested**	**N° with HIV (%)**	**N° tested**	**N° with HIV (%)**
Non-injector	172	1 (<1)	12	0 (0)	184	1 (<1)
Injector	240	2 (<1)	23	0 (0)	263	2 (<1)
p-value		0.8		---		0.8

Table 27: HCV antibody prevalence by sex and injector status

	Male		Female		Total	
Injector status	**N° tested**	**N° with HCV (%)**	**N° tested**	**N° with HCV (%)**	**N° tested**	**N° with HCV (%)**
Non-injector	174	7 (4)	12	0 (0)	186	7 (4)
Injector	242	130 (54)	23	19 (83)	265	149 (56)
p value		< 0.001		< 0.001		< 0.001

Table 28: HCV antibody prevalence by sexual identity, sex and injector status

	Male		Female		Total	
Sexual identity	**N° tested**	**N° with HCV (%)**	**N° tested**	**N° with HCV (%)**	**N° tested**	**N° with HCV (%)**
Non-injector						
Heterosexual	172	7 (4)	12	(0)	184	7 (4)
Bisexual	1	0 (0)		---	1	0 (0)
Homosexual	1	0 (0)		---	1	0 (0)
p-value		---		---		---
Injector						
Heterosexual	239	129 (54)	19	16 (84)	258	145 (56)
Bisexual	1	0 (0)	4	3 (75)	5	3 (60)
Homosexual	2	1 (50)		---	2	1 (50)
p-value		0.6		0.7		1.0

Table 29: HCV antibody prevalence by age group, sex and injector status

	Male		Female		Total	
Age group	**N° tested**	**N° with HCV (%)**	**N° tested**	**N° with HCV (%)**	**N° tested**	**N° with HCV (%)**
Non-injector						
< 20 years	19	0 (0)	1	0 (0)	20	0 (0)
20 – 24	32	1 (3)	1	0 (0)	33	1 (3)
25 – 29	28	0 (0)	1	0 (0)	29	0 (0)
30 + years	95	6 (6)	9	0 (0)	104	6 (6)
p-value		0.3		---		0.3
Injector						
< 20 years	16	1 (6)		---	16	1 (6)
20 – 24	58	23 (40)	3	2 (67)	61	25 (41)
25 – 29	60	28 (47)	8	7 (88)	68	35 (51)
30 + years	108	78 (72)	12	10 (83)	120	88 (73)
p-value		< 0.001		0.7		< 0.001

Table 30: HCV antibody prevalence by duration of drug injection and sex

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<3 years	28	1 (4)	1	0 (0)	29	1 (3)
3 to 5 years	25	11 (44)	2	1 (50)	27	12 (44)
6 to 10 years	75	34 (45)	7	6 (86)	82	40 (49)
10 + years	111	84 (76)	11	10 (91)	122	94 (77)
p-value		< 0.001		0.1		< 0.001

Table 31: HCV antibody prevalence by last drug injected and duration of drug injection

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Amphetamine	22	1 (5)	129	65 (50)	151	66 (44)
Heroin	1	0 (0)	75	63 (84)	76	63 (83)
More than one	1	0 (0)	10	7 (70)	11	7 (64)
Other/not reported	5	0 (0)	19	13 (68)	24	13 (54)
p-value		1.0		< 0.001		< 0.001

Table 32: HCV antibody prevalence by frequency of injection last month and duration of drug injection

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Less than daily	19	0 (0)	131	77 (59)	150	77 (51)
Daily or more	9	1 (11)	101	70 (69)	110	71 (65)
p-value		0.3		0.2		0.1

Table 33: HCV antibody prevalence by reuse of someone else's needle and syringe last month and duration of drug injection

Reused someone else's needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
No	18	1 (6)	116	84 (72)	134	85 (63)
Yes	3	0 (0)	24	16 (67)	27	16 (59)
p-value		0.1		0.7		0.8

Table 34: HCV antibody prevalence by imprisonment last year and duration of drug injection

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
No	12	0 (0)	79	50 (63)	91	50 (55)
Yes	17	1 (6)	149	95 (64)	166	96 (58)
p-value		0.4		1.0		0.6

Table 35: HCV antibody prevalence by years spent previously in prison, sex and injector status

Years spent previously in prison	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
No previous imprisonment	64	1 (2)	9	0 (0)	73	1 (1)
1 year or less	73	2 (3)	3	0 (0)	76	2 (3)
> 1 to 3 years	23	4 (17)	---	---	23	4 (17)
> 3 years	13	0 (0)	---	---	13	0 (0)
Not reported	1	0 (0)	---	---	1	0 (0)
p-value		0.1		---		0.008
Injector						
None	38	11 (29)	5	2 (40)	43	13 (30)
1 year or less	80	31 (39)	10	9 (90)	90	40 (44)
> 1 to 3 years	44	27 (61)	4	4 (100)	48	31 (65)
> 3 years	76	58 (76)	4	4 (100)	80	62 (78)
Not reported	4	3 (75)		---	4	3 (75)
p-value		< 0 .001		0.04		< 0.001

Table 36: HCV antibody prevalence by number of previous imprisonments, sex and injector status

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
No previous imprisonment	63	1 (2)	8	0 (0)	71	1 (1)
1 to 2	82	4 (5)	3	0 (0)	85	4 (5)
3 to 5	16	2 (13)	1	0 (0)	17	2 (12)
5 +	7	0 (0)	---	---	7	0 (0)
Not reported	6	0 (0)	---	---	6	0 (0)
p-value		0.3		---		0.3
Injector						
No previous imprisonment	38	12 (31)	3	1 (33)	41	13 (32)
1 to 2	61	24 (39)	8	6 (75)	69	30 (44)
3 to 5	84	52 (62)	6	6 (100)	90	58 (64)
5 +	55	41 (75)	6	6 (100)	61	47 (77)
Not reported	4	1 (25)	---	---	4	1 (25)
p-value		< 0.001		0.01		< 0.001

Table 37: Self-reported exposure to HCV versus serology by sex and injector status

	Hepatitis C serology*					
	Male		Female		Total	
Self-report HCV	N° tested	N° with HCV(%)	N° tested	N° with HCV(%)	N° tested	N° with HBV(%)
Non-injector						
Positive	1	1 (100)	---	---	1	1(100)
Negative	50	2 (4)	4	4 (100)	54	2 (4)
Not sure	4	1 (25)	1	0 (0)	5	1 (20)
p-value		< 0.001		---		< 0.001
Injector						
Positive	87	86 (99)	16	16 (100)	103	102 (99)
Negative	88	23 (26)	3	1 (33)	91	24 (26)
Not sure	18	12 (67)	1	1 (100)	19	13 (68)
Not reported	1	0 (0)	---	---	1	0 (0)
p-value		< 0.001		0.002		< 0.001

*Cases positive for HCV antibody.

Table 38: HCV antibody prevalence by Indigenous status, sex and injector status

	Male		Female		Total	
Indigenous Status	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
Non-Indigenous	147	5 (3)	9	0 (0)	156	5 (3)
Indigenous	25	1 (4)	3	0 (0)	28	1 (4)
p-value		0.3		---		0.003
Injector						
Non-Indigenous	195	106 (54)	15	13 (87)	210	119 (57)
Indigenous	42	23 (55)	7	5 (71)	49	28 (57)
p-value		0.3		0.6		0.5

Table 39: HCV antibody prevalence by region/country of birth, sex and injector status

	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
Australia	129	5 (4)	10	0 (0)	139	5 (4)
Other Oceania	14	0 (0)	---	---	14	0 (0)
Asia	7	1 (14)	2	0 (0)	9	1 (11)
UK & Ireland	5	0 (0)	---	---	5	0 (0)
Other	19	1 (5)	---	---	19	1 (5)
p-value		0.6		---		0.7
Injector						
Australia	209	113 (54)	23	19 (83)	232	132 (57)
Other Oceania	9	2 (22)	---	---	9	2 (22)
Asia	11	9 (82)	---	---	11	9 (82)
UK & Ireland	4	2 (50)	---	---	4	2 (50)
Other	8	4 (50)	---	---	8	4 (50)
p-value		0.1		---		0.1

Table 40: HCV antibody prevalence by main language spoken at home by parents, sex and injector status

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
English speaking	148	5 (3)	10	0 (0)	158	5 (3)
Non-English speaking	26	2 (8)	1	0 (0)	27	2 (7)
p-value		0.3		---		0.3
Injector						
English speaking	220	115 (52)	21	17 (81)	241	132 (55)
Non-English speaking	21	15 (71)	2	2 (100)	23	17 (74)
p-value		0.1		0.5		0.01

Table 41: HBV surface antigen prevalence by sex and injector status

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector	172	0 (0)	12	0 (0)	184	0 (0)
Injector	244	12 (5)	24	1 (4)	268	13 (5)
p value		0.003		0.5		0.002

Table 42: HBV core antibody prevalence by sex and injector status

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector	173	14 (8)	10	3 (30)	183	17 (9)
Injector	241	64 (27)	23	7 (30)	264	71 (27)
p-value		0.001		1.0		< 0.001

Table 43: HBV core antibody prevalence by sexual identity, sex and injector status

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector						
Heterosexual	171	14 (8)	10	3 (30)	181	17 (9)
Bisexual	1	0 (0)	---	0 (0)	1	0 (0)
Homosexual	1	0 (0)	---	---	1	0 (0)
p-value		---		---		1.0
Injector						
Heterosexual	238	64 (27)	19	6 (32)	257	70 (27)
Bisexual	1	0 (0)	4	1 (25)	5	1 (20)
Homosexual	2	0 (0)	---	---	2	0 (0)
p-value		---		0.7		1.0

Table 44: HBV core antibody prevalence by age group, sex and injector status

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector						
< 20 years	19	0 (0)	1	0 (0)	20	0 (0)
20 – 24	32	0 (0)	1	0 (0)	33	0 (0)
25 – 29	28	4 (14)	---	---	28	4 (14)
30 + years	94	10 (11)	8	3 (38)	102	13 (13)
p-value		0.2		0.6		0.2
Injector						
< 20 years	17	1 (6)	---	---	17	1 (6)
20 – 24	56	11 (20)	4	2 (50)	60	13 (22)
25 – 29	60	13 (22)	8	2 (25)	68	15 (22)
30 + years	108	39 (36)	11	3 (27)	119	42 (35)
p-value		0.03		0.6		0.05

Table 45: HBV core antibody prevalence by duration of drug injection and sex

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
<3 years	29	2 (7)	1	0 (0)	30	2 (7)
3 to 5 years	24	2 (8)	3	1 (33)	27	3 (11)
6 to 10 years	76	18 (24)	7	3 (43)	83	21 (25)
10 + years	109	41 (38)	11	3 (27)	120	44 (37)
p-value		0.01		0.8		0.01

Table 46: HBV core antibody prevalence by last drug injected and duration of drug injection

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Amphetamine	23	2 (9)	130	28 (22)	153	40 (26)
Heroin	1	0 (0)	72	22 (31)	73	22 (30)
More than one	1	0 (0)	10	2 (20)	11	2 (18)
Other/not reported	5	0 (0)	19	6 (32)	24	6 (25)
p-value		0.9		0.5		0.4

Table 47: HBV core antibody prevalence by frequency of injection last month and duration of drug injection

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Less than daily	19	2 (11)	130	42 (32)	149	44 (30)
Daily or more	10	0 (0)	100	26 (26)	110	26 (24)
p-value		0.5		0.8		0.7

Table 48: HBV core antibody prevalence by reuse of someone else's needle and syringe last month and duration of drug injection

Reused someone else's needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
No	19	1 (5)	116	39 (34)	135	40 (30)
Yes	3	0 (0)	24	6 (25)	27	6 (22)
p-value		0.7		0.8		0.8

Table 49: HBV core antibody prevalence by imprisonment last year and duration of drug injection

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
No	12	0 (0)	79	29 (37)	91	29 (32)
Yes	18	2 (11)	147	37 (25)	165	39 (24)
p-value		0.4		0.2		0.4

Table 50: HBV core antibody prevalence by years spent previously in prison, sex and injector status

Years spent previously in prison	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HCBV (%)
Non-injector						
No previous imprisonment	64	1 (2)	7	3 (43)	71	4 (6)
1 year or less	73	7 (10)	3	0 (0)	76	7 (9)
> 1 to 3 years	23	5 (22)		---	23	5 (22)
> 3 years	12	1 (8)		---	12	1 (8)
Not reported	1	0 (0)		---	1	0 (0)
p-value		0.2		0.2		0.5
Injector						
No previous imprisonment	39	8 (21)	5	1 (20)	44	9 (21)
1 year or less	80	17 (21)	11	3 (27)	91	20 (22)
> 1 to 3 years	44	11 (25)	3	2 (67)	47	13 (27)
> 3 years	74	27 (37)	4	1 (25)	78	28 (36)
Not reported	4	1 (25)	---	---	4	1 (25)
p-value		< 0.001		0.5		< 0.001

Table 51: HBV core antibody prevalence by number of previous imprisonments, sex and injector status

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector						
No previous imprisonment	63	1 (2)	6	3 (50)	69	4 (6)
1 to 2	82	9 (11)	3	0 (0)	85	9 (11)
3 to 5	16	3 (19)	1	0 (0)	17	3 (18)
5 +	7	1 (14)		---	7	1 (14)
Not reported	5	0 (0)		---	5	0 (0)
p-value		0.3		0.2		0.8
Injector						
No previous imprisonment	38	8 (21)	3	0 (0)	41	8 (20)
1 to 2	62	9 (15)	7	2 (29)	69	11 (16)
3 to 5	83	25 (30)	7	2 (29)	90	27 (30)
5 +	54	21 (39)	6	3 (50)	60	24 (40)
Not reported	3	1 (33)	---	---	3	1 (33)
p-value		< 0.001		0.05		< 0.001

Table 52: Self reported hepatitis B immunisation versus serology results

Self reported number of hepatitis B vaccinations received	Serological markers of immunity*					
	Male		Female		Total	
	Nº tested	Nº immune (%)	Nº tested	Nº immune (%)	Nº tested	Nº immune (%)
Nil vaccinations received	123	14 (11)	8	3 (38)	131	17 (13)
One vaccination	15	3 (20)	---	---	15	3 (20)
Two vaccinations	24	10 (42)	3	0 (0)	27	10 (37)
Three or more vaccinations	110	64 (58)	8	4 (50)	118	68 (58)
Unsure or not reported	49	8 (16)	4	1 (25)	53	9 (17)
Total	321	99 (31)	23	8 (35)	344	107 (31)
p-value		< 0.001		0.5		<0.001

*Surface antibody levels of $\geq$10 are considered immune. HBV core antibody positive cases have been excluded.

Table 53: Prevalence of serological markers of HBV immunity from vaccination* by number of previous imprisonments, sex and injector status**

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° immune to HBV(%)	N° tested	N° immune to HBV(%)	N° tested	N° immune to HBV(%)
Non-injector						
No previous imprisonment	62	10 (16)	5	2 (40)	67	12 (18)
1 to 2	73	18 (25)	3	0 (0)	76	18 (24)
3 to 5	13	2 (15)	1	1 (100)	14	3 (21)
5 +	6	1 (17)	---	---	6	1 (17)
Not reported	5	0 (0)	---	---	5	0 (0)
p-value		0.7		0.2		0.7
Injector						
No previous imprisonment	30	6 (20)	3	0 (0)	33	6 (18)
1 to 2	54	18 (33)	5	3 (60)	59	21 (36)
3 to 5	58	31 (53)	6	3 (50)	64	34 (53)
5 +	35	16 (46)	3	1 (33)	38	17 (45)
Not reported	3	2 (67)	---	---	3	2 (67)
p-value		0.01		0.4		0.01

*Cases with HBV surface antibody levels of ten or more are considered to be immune

** HBV core antibody positive cases have been excluded

Table 54: Prevalence of serological markers of HBV immunity from vaccination by years spent previously in prison, sex and injector status**

Years spent previously in prison	Male		Female		Total	
	N° tested	N° immune to HBV(%)	N° tested	N° immune to HBV(%)	N° tested	N° immune to HBV(%)
Non-injector						
No previous imprisonment	63	10 (16)	4	1 (25)	67	11 (16)
1 year or less	60	15 (25)	3	1 (33)	63	16 (25)
> 1 to 3 years	18	4 (22)	---	---	18	4 (22)
> 3 years	11	2 (18)	---	---	11	2 (18)
Not reported	1	0 (0)	---	---	1	0 (0)
p-value		0.8		1.0		0.7
Injector						
No previous imprisonment	31	6 (19)	4	1 (25)	35	7 (20)
1 year or less	64	23 (36)	8	3 (38)	72	26 (36)
> 1 to 3 years	34	15 (44)	2	1 (50)	36	16 (44)
> 3 years	48	28 (58)	3	2 (67)	51	30 (59)
Not reported	3	1 (33)	---	---	3	1 (33)
p-value		0.003		0.7		0.007

*Cases with HBV surface antibody levels of ten or more are considered to be immune

**HBV core antibody positive cases have been excluded

Table 55: Self-reported exposure to HBV versus serology by sex and injector status

Self-report HBV	Hepatitis B serology*					
	Male		Female		Total	
	N° tested	N° with HBV(%)	N° tested	N° with HBV(%)	N° tested	N° with HBV(%)
Non-injector						
Yes	2	1 (50)	---	---	2	1 (50)
No	161	13 (8)	9	0 (0)	170	16 (9)
Not sure	10	0 (0)	1	0 (0)	11	0 (0)
p-value		0.2		0.5		0.3
Injector						
Yes	34	28 (82)	4	3 (75)	38	31 (82)
No	187	30 (16)	18	4 (22)	205	34 (17)
Not sure	20	6 (30)	1	0 (0)	21	6 (29)
p-value		< 0. 001		0.9		< 0.001

*Cases positive for HBV core antibody

Table 56: HBV serology results by Indigenous status

Indigenous Status	Nº tested	Nº (%) with no evidence of immunity	Nº (%) with vaccination conferred immunity	Nº (%) immune through previous infection	Nº (%) who are HBV carriers
Non-Indigenous	372	223 (60)	85 (23)	55 (15)	9 (2)
Indigenous	78	26 (33)	30 (39)	18 (23)	4 (5)
Total	450	249 (56)	115 (26)	73 (16)	13 (3)
p – value	< 0.001	---	---	---	---

Table 57: HBV core antibody prevalence by Indigenous status, sex and injector status

Indigenous Status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector						
Non-Indigenous	147	11 (7)	8	3 (38)	155	14 (9)
Indigenous	24	3 (13)	2	0 (0)	26	3 (12)
p-value		0.1		0.3		0.1
Injector						
Non-Indigenous	193	46 (24)	15	4 (27)	208	50 (24)
Indigenous	43	17 (40)	7	2 (29)	50	19 (38)
p-value		0.3		0.3		0.3

Table 58: HBV core antibody prevalence by region/country of birth, sex and injector status

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector						
Australia	128	7 (5)	8	1 (13)	136	8 (6)
Other Oceania	14	4 (29)		---	14	4 (29)
Asia	7	1 (14)	2	2 (100)	9	3 (33)
UK & Ireland	5	0 (0)		---	5	0 (0)
Other	19	2 (11)		---	19	2 (11)
p-value		0.04		0.02		0.005
Injector						
Australia	209	56 (27)	23	7 (30)	232	63 (27)
Other Oceania	9	2 (22)		---	9	2 (22)
Asia	10	5 (50)		---	10	5 (50)
UK & Ireland	4	1 (25)		---	4	1 (25)
Other	8	0 (0)		---	8	0 (0)
p-value		0.05		---		0.1

Table 59: HBV core antibody prevalence by main language spoken at home by parents, sex and injector status

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector						
English speaking	147	10 (7)	8	0 (0)	155	11 (7)
Non-English speaking	26	4 (15)	2	0 (0)	28	6 (21)
p-value		0.18		---		0.003
Injector						
English speaking	220	56 (25)	21	6 (29)	241	62 (26)
Non-English speaking	20	8 (40)	2	1 (50)	22	9 (41)
p-value		0.08		0.5		0.06

Table 60 : Number (%) of respondents by demographic characteristics sex and injector status

Demographic characteristics	Non-injector	Injector	Total
N^{o} surveyed	N = 127	N = 183	N = 310*
Sex (%)			
Male	118 (93)	152 (83)	270 (87)
Female	9 (7)	30 (16)	39 (13)
Transgender	---	1 (<1)	1 (<1)
Sexual identity (%)			
Heterosexual	123 (97)	171 (93)	294 (95)
Bisexual	1 (<1)	7 (4)	8 (3)
Homosexual	2 (2)	5 (3)	7 (2)
Not reported	1 (<1)	---	1 (<1)
Age and duration of injection (years)			
Median age	32	30	31
Age range	18 - 75	18 - 58	18 - 75
Age group (%)			
<25 years	39 (31)	47 (26)	86 (28)
25+ years	88 (69)	136 (74)	224 (72)
Median age 1st IDU	---	18	---
Age range	---	9 - 41	---
Median years IDU	---	10	---
Range	---	<1 – 31	---
Duration of drug injection (%)			
<3 years	---	16 (9)	16 (5)
3+ years	---	163 (89)	163 (52)
Not reported	---	4 (2)	4 (1)
Aboriginal and Torres Strait Islander origin (%)			
No	118 (93)	155 (85)	273 (88)
Yes	9 (7)	28 (15)	37 (12)
Region / Country of birth (%)			
Australia	87 (69)	156 (85)	243 (78)
Other Oceania	8 (6)	3 (2)	11 (4)
Asia	11 (9)	11 (6)	22 (7)
UK & Ireland	5 (4)	3 (2)	8 (3)
Other	16 (13)	10 (5)	26 (8)
Main language spoken at home by parents (%)			
English speaking	99 (78)	159 (87)	258 (83)
Non-English speaking	28 (22)	24 (13)	52 (17)
Imprisonment last year (%)			
No	96 (76)	84 (46)	180 (59)
Yes	28 (22)	99 (54)	127 (41)
Injected in prison last month (%)			
Yes	---	3 (2)	3 (<1)
No	127 (0)	180 (98)	307 (99)
Not reported	3 (2)		3 (<1)
Frequency of injection last month (%)			
Not last month	---	55 (30)	55 (18)
Less than weekly	---	29 (16)	29 (9)
Weekly not daily	---	14 (8)	14 (5)
Daily or more	---	83 (45)	83 (27)
Not reported	---	2 (1)	2 (<1)

*Total excludes prison entrants who did not disclose injector status

Table 61: Number (%) of respondents by last drug injected and injecting behaviour in the month prior to survey

Injecting behaviour

Last drug injected (%)	**N = 183**	
Amphetamine	73	(40)
Anabolic steroids	1	(1)
Cocaine	7	(4)
Heroin	86	(47)
Heroin + Cocaine	2	(1)
Methadone	6	(3)
Morphine	1	(1)
Other	7	(4)
No. injected last month	**N = 128**	
Places injected last month (%)**		
Prison	3	(2)
Own home	99	(77)
Friend's home	54	(42)
Dealer's home	21	(16)
Street, park, beach	40	(31)
Car	37	(29)
Public toilet	29	(23)
Shooting room	6	(5)
MSIC*	5	(4)
Squat	10	(8)
Train, bus or cab	5	(4)
Not reported	3	(2)
Use of new sterile needles & syringes last month (%)		
All injections	86	(67)
Most of the time	20	(16)
Half of the time	8	(6)
Some of the time	12	(9)
Not last month	2	(2)

*Medically Supervised Injecting Centre

Re-used someone else's needle & syringe last month (%)		
None	116	(91)
Once	4	(3)
Twice	3	(2)
3 - 5 times	4	(3)
More than five	1	(<1)
Number of people needle & syringe was re-used with after last month (%)		
None	117	(91)
One	8	(6)
Two	2	(2)
Three to five	1	(<1)
More than five		---
Relationship to people needle & syringe was re-used after last month (%) **		
Regular sex partner	4	(3)
Casual sex partner	1	(<1)
Close friend	3	(2)
Acquaintance	3	(2)
Stranger	1	(<1)
Equipment used after someone else last month (%)**		
Spoon	28	(22)
Water	19	(15)
Filter	17	(13)
Tourniquet	10	(8)
Drug mix	18	(14)
Injected by someone after that person injected themselves or others last month (%)		
No	110	(86)
Yes	16	(13)
Not reported	2	(2)

**More than one option could be selected

Table 62: Number (%) of respondents by treatment for drug use and injector status

	Non-injector		Injector		Total	
Nº Surveyed	N = 127		N = 183		N = 310	
Any treatment/therapy for drug use (%)						
No	118	(93)	89	(49)	207	(67)
Yes	9	(7)	93	(51)	102	(33)
Not reported		---	1	(<1)	1	(<1)
History of methadone treatment (%)						
Currently		---	44	(24)	44	(14)
Previously	2	(2)	50	(27)	52	(17)
Never	125	(98)	88	(48)	213	(69)
Not reported		---	1	(1)	1	(<1)
History of other pharmacotherapy treatment (%)						
Never	126	(99)	139	(76)	265	(86)
Currently		---	9	(5)	9	(3)
Previously	1	(<1)	31	(17)	32	(10)
Not reported		---	4	(2)	4	(1)

Table 63: Number (%) of respondents by site of needle and syringe acquisition last month

Needle and syringe acquisition		
Nº surveyed	N =129	
From an NSP last month (%)		
Daily or almost daily	17	(6)
A couple of times each week	21	(7)
Less than weekly	14	(5)
Once last month	24	(8)
Not in the last month	28	(9)
Not reported	25	(8)
From a chemist last month (%)		
Daily or almost daily	5	(2)
A couple of times each week	17	(6)
Less than weekly	30	(10)
Once last month	19	(6)
Not in the last month	54	(17)
Not reported	4	(3)

Table 64: Number (%) of respondents by sexual behaviour in the month prior to survey and injector status

Sexual Behaviour	Non-injector		Injector		Total	
Nº surveyed	N = 127		N = 183		N = 310	
Sex last month (%)						
No	38	(30)	47	(26)	85	(27)
Yes	86	(68)	136	(74)	222	(72)
Condom use at last sex (%)						
No	85	(67)	136	(74)	221	(71)
Yes	39	(31)	47	(26)	86	(28)
Condom use with regular sex partner(s) last month (%)*						
No	57	(81)	83	(84)	140	(83)
Sometimes	7	(10)	8	(8)	15	(9)
Always	6	(9)	8	(8)	14	(8)
Condom use with new sex partner(s) last month (%)*						
No	2	(22)	6	(27)	8	(26)
Sometimes	1	(11)	6	(27)	7	(23)
Always	6	(67)	10	(45)	16	(52)
Condom use with casual sex partner(s) last month (%)*						
No	8	(40)	17	(40)	25	(40)
Sometimes	4	(20)	9	(21)	13	(21)
Always	8	(40)	17	(40)	25	(40)
Duration of regular sexual relationship (%)*						
One month	---	---	2	(3)	2	(1)
2 - 6 months	4	(6)	7	(8)	11	(8)
6 - 12 months	7	(10)	3	(4)	10	(7)
> 12 months	53	(82)	70	(85)	123	(84)
Sex work last month (%)**						
No	122	(96)	178	(97)	300	(97)
Yes		---	5	(3)	5	(2)
Not reported	5	(4)			5	(2)
Condom used at last sex work last month (%)**						
No		---	2	(50)	2	(50)
Yes		---	2	(50)	2	(50)

*Percentages exclude missing data and participants reporting no regular, new or casual sex partners in the previous month

**Percentages exclude missing data

Table 65: Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, Hepatitis B vaccination and treatment for HCV by injector status

	Non-injector	Injector	Total
N° surveyed	N = 127	N = 183	N = 310
Previous HIV test (%)			
Yes, last year	23 (18)	96 (52)	119 (38)
> 1 year ago	31 (25)	59 (32)	90 (29)
Never tested	72 (57)	27 (15)	99 (32)
Not reported	---	1 (1)	1 (<1)
HBV infection (%)			
No	115 (91)	131 (72)	246 (79)
Yes	3 (2)	34 (19)	37 (12)
Don't know	9 (7)	18 (10)	27 (9)
Hepatitis B vaccination (%)*	N = 124	N= 149	N = 283
No	57 (46)	45 (30)	102 (36)
Yes	32 (26)	81 (54)	113 (40)
Don't know	32 (26)	23 (15)	55 (19)
Not reported	3 (2)	---	3 (1)
Previous HCV test (%)			
Yes, last year	85 (67)	23 (13)	108 (35)
> 1 year ago	23 (18)	85 (46)	108 (35)
Never tested	17 (13)	72 (39)	89 (29)
Not reported	1 (<1)	2 (1)	3 (1)
Any treatment for HCV (%)**	N = 1	N = 95	N = 96
Interferon	---	---	---
Interferon & Ribavirin	---	2 (2)	2 (2)
Other	---	---	---
No treatment	1 (100)	93 (98)	94 (98)
Current treatment for HCV			
Interferon	---	---	---
Interferon & Ribavirin	---	---	---
Other	---	---	---

*Participants who reported a previous HBV infection have been excluded.

**Participants who did not self-report being HCV antibody positive have been excluded.

Table 66: HIV prevalence by sex and injector status

	Male		Female		Total	
Injector status	**N° tested**	**N° with HIV (%)**	**N° tested**	**N° with HIV (%)**	**N° tested**	**N° with HIV (%)**
Non-injector	75	0 (0)	5	0 (0)	80	0 (0)
Injector	104	2 (2)	16	0 (0)	120	2 (2)

Table 67: HCV antibody prevalence by sex and injector status

	Male		Female		Total	
Injector status	**N° tested**	**N° with HCV (%)**	**N° tested**	**N° with HCV (%)**	**N° tested**	**N° with HCV (%)**
Non-injector	75	2 (3)	5	0 (0)	80	2 (3)
Injector	108	72 (67)	16	13 (81)	124	85 (69)
p-value		< 0.001		0.001		< 0.001

Table 68: HCV antibody prevalence by sexual identity, sex and injector status

	Male		Female		Total	
Sexual identity	**N° tested**	**N° with HCV (%)**	**N° tested**	**N° with HCV (%)**	**N° tested**	**N° with HCV (%)**
Non-injector						
Heterosexual	74	2 (3)	5	0 (0)	79	2 (3)
Bisexual	---	---	---	---	---	---
Homosexual	1	0 (0)	---	---	1	0 (0)
p-value		0.9		---		0.8
Injector						
Heterosexual	106	71 (67)	13	11 (84)	119	82 (69)
Bisexual	---	---	3	2 (67)	3	2 (67)
Homosexual	2	1 (50)	---	---	2	1 (50)
p-value		0.6		0.5		0.8

Table 69: HCV antibody prevalence by age group, sex and injector status

	Male		Female		Total	
Age group	**N° tested**	**N° with HCV (%)**	**N° tested**	**N° with HCV (%)**	**N° tested**	**N° with HCV (%)**
Non-injector						
< 20 years	8	0 (0)	1	0 (0)	9	0 (0)
20 – 24	16	0 (0)	---	---	16	0 (0)
25 – 29	13	0 (0)	---	---	13	0 (0)
30 + years	38	2 (5)	4	0 (0)	42	2 (5)
p-value		0.5		---		0.6
Injector						
< 20 years	5	0 (0)	---	---	5	0 (0)
20 – 24	28	16 (57)	3	2 (67)	31	18 (58)
25 – 29	27	14 (52)	4	3 (75)	31	17 (55)
30 + years	48	42 (88)	9	8 (89)	57	50 (88)
p-value		< 0.001		0.6		< 0.001

Table 70: HCV antibody prevalence by duration of drug injection and sex

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<3 years	11	1 (9)	1	0 (0)	12	1 (8)
3 to 5 years	11	7 (64)	2	1 (50)	13	8 (62)
6 to 10 years	35	20 (57)	5	4 (80)	40	24 (60)
10 + years	50	44 (88)	8	8 (100)	58	52 (90)
p-value		< 0.001		0.06		< 0.001

Table 71: HCV antibody prevalence by last drug injected and duration of drug injection

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Amphetamine	6	1 (17)	42	26 (62)	49	27 (56)
Heroin	1	0 (0)	55	47 (86)	56	47 (84)
More than one	---	---	4	3 (75)	4	3 (75)
Other/not reported	5	0 (0)	10	8 (80)	15	8 (53)
p-value		0.6		0.06		0.008

Table 72: HCV antibody prevalence by frequency of injection last month and duration of drug injection

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Less than daily	9	0 (0)	59	45 (76)	69*	45 (65)
Daily or more	2	1 (50)	52	39 (75)	54	40 (74)
p-value		0.7		0.9		0.2

*Total includes one case who did not report duration of IDU

Table 73: HCV antibody prevalence by reuse of someone else's needle and syringe last month and duration of drug injection

Reused someone else's needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
No	8	1 (13)	65	53 (82)	74*	54 (73)
Yes	1	0 (0)	8	3 (38)	9	3 (33)
p-value		0.7		0.01		0.02

*Total includes those who did not report duration of IDU

Table 74: HCV antibody prevalence by imprisonment last year and duration of drug injection

Imprisonment last year	<3 years IDU		3+ years IDU		Total*	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
No	6	0 (0)	53	39 (74)	60*	39 (65)
Yes	6	1 (17)	58	45 (78)	64	46 (72)
p-value		0.3		0.6		0.4

* Total includes those who did not report duration of IDU

Table 75: HCV antibody prevalence by years spent previously in prison, sex and injector status

Years spent previously in prison	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
No previous imprisonment	44	1 (2)	4	0 (0)	48	1 (2)
1 year or less	19	0 (0)	1	0 (0)	20	0 (0)
> 1 to 3 years	8	1 (13)	---	---	8	1 (13)
> 3 years	4	0 (0)	---	---	4	0 (0)
p-value		0.3		---		0.3
Injector						
No previous imprisonment	17	7 (41)	4	2 (50)	21	9 (43)
1 year or less	27	15 (56)	8	7 (88)	35	22 (63)
> 1 to 3 years	23	17 (74)	---	---	23	17 (74)
> 3 years	37	30 (81)	4	4 (100)	41	34 (83)
Not reported	4	2 (75)	---	---	4	2 (50)
p-value		0.3		0.2		0.2

Table 76: HCV antibody prevalence by number of previous imprisonments, sex and injector status

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
No previous imprisonment	43	1 (2)	4	0 (0)	47	1 (2)
1 to 2	23	0 (0)	1	0 (0)	24	0 (0)
3 to 5	6	1 (17)	---	---	6	1 (17)
5 +	2	0 (0)	---	---	2	0 (0)
Not reported	1	0 (0)	---	---	1	0 (0)
p-value		0.3		---		0.2
Injector						
No previous imprisonment	17	8 (47)	2	1 (50)	19	9 (47)
1 to 2	20	11 (55)	5	3 (60)	25	14 (56)
3 to 5	34	25 (74)	5	5 (100)	39	30 (77)
5 +	35	27 (77)	4	4 (100)	39	31 (80)
Not reported	2	1 (50)	---	---	2	1 (50)
p-value		0.1		0.2		0.05

Table 77: Self-reported exposure to HCV versus serology by sex and injector status

	Hepatitis C serology					
	Male		Female		Total	
Self-report HCV	N° tested	N° with HCV(%)	N° tested	N° with HCV(%)	N° tested	N° with HBV(%)
Non-injector						
Positive	---	---	---	---	---	---
Negative	16	0 (0)	1	0 (0)	17	0 (0)
Not sure	1	0 (0)	1	0 (0)	2	0 (0)
p-value		---		---		---
Injector						
Positive	45	44 (98)	12	12 (100)	57	56 (98)
Negative	29	12 (41)	3	1 (33)	32	13 (41)
Not sure	13	9 (69)		---	13	9 (69)
Not reported	1	0 (0)		---	1	0 (0)
p-value		< 0.001		< 0.001		< 0.001

Table 78: HCV antibody prevalence by Indigenous status, sex and injector status

	Male		Female		Total	
Indigenous Status	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
Non-Indigenous	72	2 (3)	5	0 (0)	77	2 (3)
Indigenous	3	0 (0)	---	---	3	0 (0)
p-value		0.8		---		0.8
Injector						
Non-Indigenous	91	61 (67)	12	10 (83)	103	71 (69)
Indigenous	17	11 (65)	4	3 (75)	21	14 (67)
p-value		0.9		0.7		0.8

Table 79: HCV antibody prevalence by region/country of birth, sex and injector status

	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
Australia	48	1 (2)	3	0 (0)	51	1 (2)
Other Oceania	6	0 (0)	---	---	6	0 (0)
Asia	4	0 (0)	2	0 (0)	6	0 (0)
UK & Ireland	3	0 (0)	---	---	3	0 (0)
Other	14	1 (7)	---	---	14	1 (7)
p-value		0.8		---		0.8
Injector						
Australia	90	59 (66)	16	13 (81)	106	72 (68)
Other Oceania	1	0 (0)	---	---	1	0 (0)
Asia	10	8 (80)	---	---	10	8 (80)
UK & Ireland	2	2 (100)	---	---	2	2 (100)
Other	5	3 (60)	---	---	5	3 (60)
p-value		0.4		---		0.4

Table 80: HCV antibody prevalence by main language spoken at home by parents, sex and injector status

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
English speaking	57	1 (2)	3	0 (0)	60	1 (2)
Non-English speaking	18	1 (6)	2	0 (0)	20	1 (5)
p-value		0.4		---		0.4
Injector						
English speaking	89	58 (65)	15	12 (80)	104	70 (67)
Non-English speaking	19	14 (74)	1	1 (100)	20	15 (75)
p-value		0.5		0.6		0.5

Table 81: HBV surface antigen prevalence by sex and injector status

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector	75	0 (0)	5	0 (0)	80	0 (0)
Injector	108	6 (6)	16	0 (0)	124	6 (5)
p-value		0.04		---		0.05

Table 82: HBV core antibody prevalence by sex and injector status

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector	75	6 (8)	5	2 (60)	80	9 (11)
Injector	107	35 (33)	16	3 (19)	123	38 (31)
p-value		< 0.001		0.8		0.01

Table 83: HBV core antibody prevalence by sexual identity, sex and injector status

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector						
Heterosexual	74	6 (8)	5	3 (60)	79	9 (11)
Bisexual	---	---	---	---	---	---
Homosexual	1	0 (0)	---	---	1	0 (0)
p-value		0.9		---		0.9
Injector						
Heterosexual	105	35 (33)	13	2 (15)	118	37 (31)
Bisexual	---	---	3	1 (33)	3	1 (33)
Homosexual	2	0 (0)	---	---	2	0 (0)
p-value		0.6		0.5		0.9

Table 84: HBV core antibody prevalence by age group, sex and injector status

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector						
< 20 years	8	0 (0)	1	0 (0)	9	0 (0)
20 – 24	16	0 (0)	---	---	16	0 (0)
25 – 29	13	2 (15)	---	---	13	0 (0)
30 + years	38	4 (11)	4	3 (75)	42	1 (2)
p-value		0.6		0.2		0.5
Injector						
< 20 years	5	0 (0)	---	---	5	0 (0)
20 – 24	27	9 (33)	3	1 (33)	30	10 (33)
25 – 29	27	6 (22)	4	0 (0)	31	6 (19)
30 + years	48	20 (42)	9	2 (22)	57	22 (39)
p-value		0.2		0.5		0.2

Table 85: HBV core antibody prevalence by duration of drug injection and sex

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
<3 years	11	0 (0)	1	0 (0)	12	0 (0)
3 to 5 years	10	2 (20)	2	0 (0)	12	2 (17)
6 to 10 years	35	12 (34)	5	1 (20)	40	13 (33)
10 + years	50	21 (42)	8	2 (25)	58	23 (40)
p-value		0.1		0.8		0.1

Table 86: HBV core antibody prevalence by last drug injected and duration of drug injection

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Amphetamine	6	0 (0)	42	16 (38)	49	16 (33)
Heroin	1	0 (0)	54	18 (33)	55	18 (33)
More than one	---	---	4	1 (25)	4	1 (25)
Other/not reported	5	0 (0)	10	3 (30)	15	3 (20)
p-value		---		0.9		0.7

Table 87: HBV core antibody prevalence by frequency of injection last month and duration of drug injection

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Less than daily	9	0 (0)	59	24 (41)	69	24 (35)
Daily or more	2	0 (0)	51	14 (28)	53	14 (26)
p-value		---		0.3		0.8

Table 88: HBV core antibody prevalence by reuse of someone else's needle and syringe last month and duration of drug injection

Reused someone else's needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
No	8	0 (0)	64	22 (34)	73	22 (30)
Yes	1	0 (0)	8	2 (25)	9	2 (22)
p-value		---		0.8		0.8

Table 89: HBV core antibody prevalence by imprisonment last year and duration of drug injection

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
No	6	0 (0)	53	20 (38)	60	20 (33)
Yes	6	0 (0)	57	18 (32)	63	18 (29)
p-value		---		0.8		0.8

Table 90: HBV core antibody prevalence by years spent previously in prison, sex and injector status

Years spent previously in prison	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HCBV (%)
Non-injector						
No previous imprisonment	44	1 (2)	4	3 (75)	48	4 (8)
1 year or less	19	1 (5)	1	0 (0)	20	1 (5)
> 1 to 3 years	8	3 (38)	---	---	8	3 (38)
> 3 years	4	1 (25)	---	---	4	1 (25)
p-value		0.03		0.2		0.2
Injector						
No previous imprisonment	18	3 (17)	4	1 (25)	22	4 (18)
1 year or less	26	8 (31)	8	1 (13)	34	9 (27)
> 1 to 3 years	23	7 (30)	---	---	23	7 (30)
> 3 years	36	16 (44)	4	1 (25)	40	17 (42)
Not reported	4	1 (25)	---	---	4	1 (25)
p-value		0.02		0.8		0.01

Table 91: HBV core antibody prevalence by number of previous imprisonments, sex and injector status

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector						
No previous imprisonment	43	1 (2)	4	3 (75)	47	4 (8)
1 to 2	23	1 (4)	1	0 (0)	24	1 (4)
3 to 5	6	3 (50)		---	6	3 (50)
5 +	2	1 (50)		---	2	1 (50)
Not reported	1	0 (0)		---	1	0 (0)
p-value		0.01		0.2		0.07
Injector						
No previous imprisonment	17	3 (18)	2	0 (0)	19	3 (16)
1 to 2	20	6 (30)	5	1 (20)	25	7 (28)
3 to 5	34	11 (32)	5	0 (0)	39	11 (28)
5 +	34	15 (44)	4	2 (50)	38	17 (45)
Not reported	2	0 (0)		---	2	0 (0)
p-value		< 0.001		0.2		< 0.001

Table 92: Prevalence of serological markers of HBV immunity from vaccination by number of previous imprisonments, sex and injector status**

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° immune to HBV (%)	N° tested	N° immune to HBV (%)	N° tested	N° immune to HBV (%)
Non-injector						
No previous imprisonment	42	4 (10)	1	1 (100)	43	5 (12)
1 to 2	22	3 (14)	1	0 (0)	23	3 (13)
3 to 5	3	1 (33)	---	---	3	1 (33)
5 +	1	0 (0)	---	---	1	0 (0)
Not reported	1	0 (0)	---	---	1	0 (0)
p-value		0.8		0.2		0.8
Injector						
No previous imprisonment	14	3 (21)	2	0 (0)	16	3 (19)
1 to 2	14	4 (29)	4	2 (50)	18	6 (33)
3 to 5	23	7 (30)	5	2 (40)	28	9 (32)
5 +	19	5 (26)	2	1 (50)	21	6 (29)
Not reported	2	1 (50)	---	---	2	1 (50)
p-value		0.9		0.7		0.8

*Cases with HBV surface antibody levels of ten or more are considered immune

**HBV core antibody positive cases have been excluded

Table 93: Self reported hepatitis B immunisation versus serology results

Self reported number of hepatitis B vaccinations received	Serological markers of immunity*					
	Male		Female		Total	
	Nº tested	Nº immune (%)	Nº tested	Nº immune (%)	Nº tested	Nº immune (%)
Nil vaccinations received	56	5 (9)	3	1 (33)	59	6 (10)
One vaccination	7	2 (29)	---	---	7	2 (29)
Two vaccinations	8	3 (38)	3	0 (0)	11	3 (27)
Three or more vaccinations	31	14 (45)	7	4 (57)	38	18 (47)
Unsure or not reported	36	3 (8)	2	1 (50)	38	4 (11)
Total	138	27 (20)	15	6 (40)	153	33 (22)
p-value		< 0.001		0.4		< 0.001

*Surface antibody levels of $\geq$10 are considered immune. HBV core antibody positive cases have been excluded.

Table 94: Prevalence of serological markers of HBV immunity from vaccination by duration of previous imprisonment, sex and injector status**

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° immune to HBV (%)	N° tested	N° immune to HBV (%)	N° tested	N° immune to HBV (%)
Non-injector						
No previous imprisonment	42	4 (10)	1	1 (100)	43	5 (12)
1 year or less	18	3 (17)	1	0 (0)	19	3 (16)
> 1 to 3 years	5	1 (20)	---	---	5	1 (20)
> 3 years	3	0 (0)	---	---	3	0 (0)
p-value		0.7		0.2		0.8
Injector						
No previous imprisonment	15	3 (20)	3	1 (33)	18	4 (22)
1 year or less	18	5 (28)	7	2 (29)	25	7 (28)
> 1 to 3 years	15	3 (20)	---	---	15	3 (20)
> 3 years	20	8 (40)	3	2 (67)	23	10 (43)
Not reported	2	0 (0)	---	---	2	0 (0)
p-value		0.5		0.5		0.4

*Cases with HBV surface antibody levels of ten or more are considered immune

** HBV core antibody positive cases have been excluded

Table 95: Self-reported exposure to HBV versus serology by sex and injector status

Self-report HBV	Hepatitis B serology*					
	Male		Female		Total	
	N° tested	N° with HBV(%)	N° tested	N° with HBV(%)	N° tested	N° with HBV(%)
Non-injector						
Positive	---	---	---	---	---	---
Negative	69	6 (9)	5	3 (60)	74	9 (12)
Not sure	6	0 (0)	---	---	6	0 (0)
p-value		0.7		---		0.6
Injector						
Positive	21	16 (76)	2	1 (50)	23	17 (74)
Negative	71	15 (21)	14	2 (14)	85	17 (20)
Not sure	15	4 (27)	---	---	---	---
p-value		< 0.001		0.2		< 0.001

*Cases positive for HBV core antibody

Table 96: HBV serology results by Indigenous status

Indigenous Status	Nº tested	Nº (%) with no evidence of immunity	Nº (%) with vaccination conferred immunity	Nº (%) immune through previous infection	Nº (%) who are HBV carriers
Non-Indigenous	179	112 (63)	28 (16)	35 (20)	4 (2)
Indigenous	25	10 (40)	6 (24)	7 (28)	2 (8)
Total	204	122 (60)	34 (17)	42 (21)	6 (3)
p – value	0.1	---	---	---	---

Table 97: HBV core antibody prevalence by Indigenous status, sex and injector status

	Male		Female		Total	
Indigenous Status	**N° tested**	**N° with HBV (%)**	**N° tested**	**N° with HBV (%)**	**N° tested**	**N° with HBV ab (%)**
Non-injector						
Non-Indigenous	72	6 (8)	5	3 (60)	77	9 (12)
Indigenous	3	0 (0)	---	---	3	0 (0)
p-value		0.8		---		0.8
Injector						
Non-Indigenous	89	27 (30)	12	2 (17)	101	29 (29)
Indigenous	18	8 (44)	4	1 (25)	22	9 (41)
p-value		0.4		0.7		0.5

Table 98: HBV core antibody prevalence by region/country of birth, sex and injector status

	Male		Female		Total	
Region/Country of birth	**N° tested**	**N° with HBV (%)**	**N° tested**	**N° with HBV (%)**	**N° tested**	**N° with HBV (%)**
Non-injector						
Australia	48	2 (4)	3	1 (33)	51	3 (6)
Other Oceania	6	3 (50)	---	---	6	3 (50)
Asia	4	0 (0)	2	2 (100)	6	2 (33)
UK & Ireland	3	0 (0)	---	---	3	0 (0)
Other	14	1 (7)	---	---	14	1 (7)
p-value		0.01		0.1		0.2
Injector						
Australia	90	30 (33)	16	3 (19)	106	33 (31)
Other Oceania	1	0 (0)	---	---	1	0 (0)
Asia	9	4 (44)	---	---	9	4 (44)
UK & Ireland	2	1 (50)	---	---	2	1 (50)
Other	5	0 (0)	---	---	5	0 (0)
p-value		0.001		---		< 0.001

Table 99: HBV core antibody prevalence by main language spoken at home by parents, sex and injector status

	Male		Female		Total	
Main language spoken at home by parents	**N° tested**	**N° with HBV (%)**	**N° tested**	**N° with HBV (%)**	**N° tested**	**N° with HBV (%)**
Non-injector						
English speaking	57	4 (7)	3	1 (33)	60	5 (8)
Non-English speaking	18	2 (11)	2	2 (100)	20	4 (20)
p-value		0.2		0.1		0.7
Injector						
English speaking	89	28 (32)	15	3 (20)	104	31 (30)
Non-English speaking	18	7 (39)	1	0 (0)	19	7 (37)
p-value		0.004		0.6		0.003

QUEENSLAND

Table 100 : Number (%) of respondents by demographic characteristics and sex by injector status

Demographic characteristics	Non-injector	Injector	Total
N° surveyed	58	82	140*
Sex (%)			
Male	58 (100)	82 (100)	140 (100)
Female	---	---	---
Transgender	---	---	---
Sexual identity (%)			
Heterosexual	56 (97)	81 (99)	137 (98)
Bisexual	2 (3)	1 (1)	3 (2)
Homosexual	---	---	---
Age and duration of injection (years)			
Median age	36	29	31
Age range	17 – 67	17 – 53	17 – 67
Age group (%)			
<25 years	12 (21)	28 (34)	40 (29)
25+ years	46 (79)	54 (66)	100 (71)
Median age 1st IDU	---	17	---
Age range	---	11-38	---
Median years IDU	---	9	---
Range	---	<1 – 28	---
Duration of drug injection (%)			
<3 years	---	9 (11)	9 (6)
3+ years	---	73 (89)	73 (52)
Aboriginal and Torres Strait Islander origin (%)			
No	52 (90)	74 (90)	126 (90)
Yes	6 (10)	8 (10)	14 (10)
Region/Country of birth (%)			
Australia	40 (69)	71 (87)	111 (79)
Other/Oceania	8 (14)	8 (10)	16 (11)
Asia	2 (3)	2 (2)	4 (3)
UK & Ireland	3 (5)	1 (1)	4 (3)
Other	5 (9)	---	5 (4)
Main language spoken at home by parents (%)			
English speaking	52 (90)	79 (96)	131 (94)
Non-English speaking	6 (10)	3 (4)	9 (6)
Imprisonment last year (%)			
No	4 (7)	1 (1)	5 (4)
Yes	54 (93)	81 (99)	135 (96)
Injected in prison last month (%)			
Yes	---	3 (4)	3 (2)
No	58 (100)	79 (96)	137 (98)
Frequency of injection last month (%)			
Not last month	---	32 (39)	32 (23)
Less than weekly	---	6 (7)	6 (4)
Weekly not daily	---	7 (9)	7 (5)
Daily or more	---	37 (45)	37 (26)

*Total excludes prison entrants who did not disclose injector status

QUEENSLAND

Table 101: Number (%) of respondents by last drug injected and injecting behaviour in the month prior to survey

Injecting behaviour

Last drug injected (%)	**N = 82**	
Amphetamine	59	(72)
Anabolic steroids		---
Cocaine		---
Heroin	20	(24)
Heroin + Cocaine		---
Methadone	1	(1)
Morphine	2	(2)
Other		---
Places injected last month (%)**	**N = 50**	
Prison	3	(6)
Own home	45	(90)
Friend's home	37	(74)
Dealers home	23	(46)
Street, Park, beach	25	(50)
Car	31	(62)
Public toilet	21	(42)
Shooting room	2	(4)
MSIC*	4	(8)
Squat	9	(18)
Use of new sterile needles & syringes last month (%)	**N = 50**	
All injections	37	(74)
Most of the time	8	(16)
Half of the time	4	(8)
Some of the time	1	(2)
Not last month		---

* Medically Supervised Injecting Centre

	N = 50	
Re-used someone else's needle & syringe last month (%)		
None	39	(78)
Once	1	(2)
Twice	4	(8)
3 - 5 times	2	(4)
More than five	4	(8)
Number of people needle & syringe was re-used with after last month (%)		
None	39	(78)
One	8	(16)
Two	2	(4)
Three to five	1	(2)
More than five		---
Not reported		---
Relationship to people needle & syringe was re-used after last month (%)* *		
Regular sex partner	8	(16)
Casual sex partner	1	(2)
Close friend	2	(4)
Acquaintance	1	(2)
Other/not specified	1	(2)
Equipment used after someone else last month (%)**		
Spoon	11	(22)
Water	42	(84)
Filter	42	(84)
Tourniquet	2	(4)
Drug mix	7	(14)
Injected by someone after that person injected themselves or others last month (%)		
No	47	(94)
Yes	3	(6)

** More than one option could be selected

Table 102: Number (%) of respondents by treatment for drug use and injector status

	Non-injector		Injector		Total	
Nº Surveyed	N = 58		N = 82		N = 140	
Any treatment/therapy for drug use (%)						
No	55	(95)	50	(61)	105	(75)
Yes	2	(3)	32	(39)	34	(24)
Not reported	1	(2)		---	1	(1)
History of methadone treatment (%)						
Currently	2	(3)	3	(4)	5	(4)
Previously	0	(0)	17	(21)	17	(12)
Never	56	(97)	62	(76)	118	(84)
History of other pharmacotherapy treatment (%)						
Never	56	(97)	66	(80)	122	(87)
Currently	2	(3)	4	(5)	6	(4)
Previously	0	(0)	12	(15)	12	(9)

Table 103: Number (%) of respondents by site of needle and syringe acquisition last month

Needle and syringe acquisition		
Nº surveyed	**N = 50**	
From an NSP last month (%)		
Daily or almost daily	11	(22)
A couple of times each week	10	(20)
Less than weekly	8	(16)
Once last month	10	(20)
Not in the last month	11	(22)
From a chemist last month (%)		
Daily or almost daily	4	(8)
A couple of times each week	12	(24)
Less than weekly	12	(24)
Once last month	7	(14)
Not in the last month	15	(30)

QUEENSLAND

Table 104: Number (%) of respondents by sexual behaviour in the month prior to survey and injector status

Sexual Behaviour	Non-injector		Injector		Total	
No surveyed	N = 58		N = 82		N = 140	
Sex last month (%)						
No	15	(26)	13	(16)	28	(20)
Yes	43	(74)	69	(84)	112	(80)
Condom use at last sex (%)						
No	44	(76)	66	(80)	110	(79)
Yes	14	(24)	16	(20)	30	(21)
Condom use with regular sex partner(s) last month (%)*						
No	29	(81)	47	(94)	76	(86)
Sometimes	2	(6)	3	(6)	5	(6)
Always	5	(14)	---		5	(6)
Condom use with new sex partner(s) last month (%)*						
No	2	(100)	8	(100)	10	(100)
Sometimes	---		---		---	
Always	---		---		---	
Condom use with casual sex partner(s) last month (%)*						
No	3	(33)	10	(50)	13	(45)
Sometimes	---		2	(10)	2	(7)
Always	6	(67)	8	(40)	14	(48)
Duration of regular sexual relationship (%)*						
One month	1	(3)	1	(2)	2	(2)
2 - 6 months	3	(8)	3	(6)	6	(7)
6 - 12 months	10	(28)	10	(19)	20	(23)
> 12 months	22	(61)	38	(73)	60	(68)
Sex work month last month (%)						
No	57	(98)	81	(99)	138	(99)
Yes	1	(2)	---		1	(<1)
Not reported	---		1	(1)	1	(<1)
Condom used at last sex work last month (%)**						
No	---		---		---	
Yes	1	(100)	---		1	(100)

*Percentages exclude missing data and participants reporting no regular, new or casual sex partners respectively in the previous month

**Percentages exclude missing data

Table 105: Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, Hepatitis B vaccination and treatment for HCV by injector status

	Non-injector	Injector	Total
N° surveyed	N = 58	N = 82	N = 140
Previous HIV test (%)			
Yes, last year	10 (17)	33 (40)	43 (31)
> 1 year ago	26 (45)	33 (40)	59 (42)
Never tested	22 (38)	16 (20)	38 (27)
HBV infection (%)			
No	56 (97)	76 (93)	132 (94)
Yes	1 (2)	6 (7)	7 (5)
Don't know	1 (2)		1 (1)
Hepatitis B vaccination (%)*	N = 57	N =76	N = 133
No	27 (47)	11 (14)	38 (29)
Yes	30 (53)	65 (86)	95 (71)
Previous HCV test (%)			
Yes, last year	9 (16)	30 (37)	39 (28)
> 1 year ago	21 (36)	43 (52)	64 (46)
Never tested	28 (48)	9 (11)	37 (26)
Any treatment for HCV (%)*			
Interferon	---	---	---
Interferon & Ribarvirin	---	---	---
Other	---	---	---
No treatment	---	---	---
Current treatment for HCV			
Interferon	---	---	---
Interferon & Ribavirin	---	---	---
Other	---	---	---

*Participants who reported a prevous HBV infection have been excluded

*Participants who did not self-report being HCV antibody positive have been excluded.

Table 106: HIV prevalence by sex and injector status

	Male		Female		Total	
Injector status	**N° tested**	**N° with HIV (%)**	**N° tested**	**N° with HIV (%)**	**N° tested**	**N° with HIV (%)**
Non-injector	53	1 (2)	---	---	53	1 (2)
Injector	77	0 (0)	---	---	77	0 (0)
p-value		0.2		---		0.2

QUEENSLAND

Table 107: HCV antibody prevalence by sex and injector status

Injector status	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector	54	2 (4)	---	---	54	2 (4)
Injector	74	36 (48)	---	---	74	36 (49)
p-value		< 0.001		---		< 0.001

Table 108: HCV antibody prevalence by sexual identity, sex and injector status

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
Heterosexual	53	2 (4)	---	---	53	2 (4)
Bisexual	1	0 (0)	---	---	1	0 (0)
Homosexual	---	---	---	---	---	---
p-value		0.8				0.8
Injector			---	---		
Heterosexual	74	36 (49)	---	---	74	36 (49)
Bisexual	1	0 (0)	---	---	1	0 (0)
Homosexual	---	---	---	---	---	---
p-value		0.3	---	---		0.3

Table 109: HCV antibody prevalence by age group, sex and injector status

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
< 20 years	4	0 (0)	---	---	4	0 (0)
20 – 24	8	0 (0)	---	---	8	0 (0)
25 – 29	7	0 (0)	---	---	7	0 (0)
30 + years	35	2 (6)	---	---	35	2 (6)
p-value		0.7		---		0.7
Injector						
< 20 years	7	0 (0)	---	---	7	0 (0)
20 – 24	19	6 (32)	---	---	19	6 (32)
25 – 29	17	11 (65)	---	---	17	11 (65)
30 + years	32	19 (59)	---	---	32	19 (59)
p-value		0.007		---		0.007

Table 110: HCV antibody prevalence by duration of drug injection and sex

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<3 years	8	0 (0)	---	---	8	0 (0)
3 to 5 years	9	1 (11)	---	---	9	1 (11)
6 to 10 years	22	10 (46)	---	---	22	10 (46)
10 + years	36	25 (69)	---	---	36	25 (69)
p-value		< 0.001		---		< 0.001

Table 111: HCV antibody prevalence by last drug injected and duration of drug of drug injection

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Amphetamine	8	0 (0)	46	20 (43)	54	20 (37)
Heroin	---	---	19	15 (79)	19	15 (79)
More than one	---	---	---	---	---	---
Other/not reported	---	---	2	1 (50)	2	1 (50)
p-value		---		0.03		0.007

Table 112: HCV antibody prevalence by frequency of injection last month and duration of drug injection

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Less than daily	5	0 (0)	37	18 (49)	42	18 (43)
Daily or more	3	0 (0)	30	18 (60)	33	18 (55)
p-value		---		0.4		0.3

Table 113: HCV antibody prevalence by reuse of someone else's needle and syringe last month and duration of drug injection

Reused someone else's needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
No	4	0 (0)	30	17 (57)	34	17 (50)
Yes	1	0 (0)	9	8 (89)	10	8 (80)
p-value		---		0.08		0.1

QUEENSLAND

Table 114: HCV antibody prevalence by imprisonment last year and duration of drug injection

Imprisonment last year	<3 years IDU		3+ years IDU		Total*	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
No	---	---	---	---	---	---
Yes	8	0 (0)	67	36 (54)	75	36 (48)
p-value		---		---		---

*Total includes those who did not report duration of IDU

Table 115: HCV antibody prevalence by years spent previously in prison, sex and injector status

Years spent previously in prison	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
No previous imprisonment	3	0 (0)	---	---	3	0 (0)
1 year or less	38	0 (0)	---	---	38	0 (0)
> 1 to 3 years	6	2 (33)	---	---	6	2 (33)
> 3 years	7	0 (0)	---	---	7	0 (0)
p-value		0.001		---		0.001
Injector						
No previous imprisonment	---	---			---	---
1 year or less	34	11 (32)	---	---	34	11 (32)
> 1 to 3 years	13	5 (38)	---	---	13	5 (29)
> 3 years	28	20 (71)	---	---	28	20 (71)
p-value		0.007		---		0.007

Table 116: HCV antibody prevalence by number of previous imprisonments, sex and injector status

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
No previous imprisonment	3	0 (0)	---	---	3	0 (0)
1 to 2	46	2 (4)	---	---	46	2 (4)
3 to 5	4	0 (0)	---	---	4	0 (0)
5 +	1	0 (0)	---	---	1	0 (0)
Not reported	1	0 (0)	---	---	1	0 (0)
p-value		0.9		---		0.9
Injector						
No previous imprisonment	---	---	---	---	---	---
1 to 2	29	7 (24)	---	---	29	7 (24)
3 to 5	37	22 (59)	---	---	37	22 (59)
5 +	9	7 (78)	---	---	9	7 (78)
p-value		0.003		---		0.003

Table 117: Self-reported exposure to HCV versus serology by sex and injector status

Self-report HCV	Hepatitis C serology*					
	Male		Female		Total	
	N° tested	N° with HCV(%)	N° tested	N° with HCV(%)	N° tested	N° with HBV(%)
Non-injector						
Positive	---	---	---	---	---	---
Negative	26	1 (4)	---	---	26	1 (4)
Not sure	---	---	---	---	---	---
p-value		---		---		---
Injector						
Positive	29	29 (100)	---	---	29	29 (100)
Negative	35	4 (11)	---	---	35	4 (11)
Not sure	4	2 (50)	---	---	4	2 (50)
p-value		< 0.001		---		< 0.001

*Cases positive for HCV antibody

Table 118: HCV antibody prevalence by Indigenous status, sex and injector status

Indigenous Status	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
Non-Indigenous	48	2 (4)	---	---	48	2 (4)
Indigenous	6	0 (0)	---	---	6	0 (0)
p-value		0.6		---		0.6
Injector						
Non-Indigenous	67	32 (48)	---	---	67	32 (48)
Indigenous	8	4 (50)	---	---	8	4 (50)
p-value		0.9		---		0.9

Table 119: HCV antibody prevalence by region/country of birth, sex and injector status

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
Australia	38	1 (3)	---	---	38	1 (3)
Other Oceania	8	0 (0)	---	---	8	0 (0)
Asia	2	1 (50)	---	---	2	1 (50)
UK & Ireland	2	0 (0)	---	---	2	0 (0)
Other	4	0 (0)	---	---	4	0 (0)
p-value		0.01		---		0.01
Injector				---		
Australia	66	33 (50)	---	---	66	33 (50)
Other Oceania	7	2 (29)	---	---	7	2 (29)
Asia	1	1 (100)	---	---	1	1 (100)
UK & Ireland	1	0 (0)	---	---	1	0 (0)
Other	---	---	---	---	---	---
p-value		0.4		---		0.4

QUEENSLAND

Table 120: HCV antibody prevalence by main language spoken at home by parents, sex and injector status

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
English speaking	48	1 (2)	---	---	48	1 (2)
Non-English speaking	6	1 (17)	---	---	6	1 (17)
p-value		0.8		---		
Injector						
English speaking	73	35 (48)	---	---	73	35 (48)
Non-English speaking	2	1 (50)	---	---	2	1 (50)
p-value		1.0		---		1.0

Table 121: HBV surface antigen prevalence by sex and injector status

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector	54	0 (0)	---	---	54	0 (0)
Injector	77	3 (4)	---	---	77	3 (4)
p-value		0.1		---		0.1

Table 122: HBV core antibody prevalence by sex and injector status

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector	54	5 (9)	---	---	54	5 (9)
Injector	74	12 (16)	---	---	74	12 (16)
p-value		0.3				0.3

Table 123: HBV core antibody prevalence by sexual identity, sex and injector status

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector						
Heterosexual	53	5 (9)	---	---	53	5 (9)
Bisexual	1	0 (0)	---	---	1	0 (0)
Homosexual	---	---	---	---	---	---
p-value		0.7		---		0.7
Injector						
Heterosexual	73	12 (16)	---	---	73	12 (16)
Bisexual	1	0 (0)	---	---	1	0 (0)
Homosexual	---	---	---	---	---	---
p-value		0.7		---		0.7

Table 124: HBV core antibody prevalence by age group, sex and injector status

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector						
< 20 years	4	0 (0)	---	---	4	0 (0)
20 – 24	8	0 (0)	---	---	8	0 (0)
25 – 29	7	1 (14)	---	---	7	1 (14)
30 + years	35	4 (11)	---	---	35	4 (11)
p-value		0.6		---		0.6
Injector						
< 20 years	8	1 (13)	---	---	8	1 (13)
20 – 24	18	1 (6)	---	---	18	1 (6)
25 – 29	17	2 (12)	---	---	17	2 (12)
30 + years	31	9 (29)	---	---	31	9 (29)
p-value		0.3		---		0.3

Table 125: HBV core antibody prevalence by duration of drug injection and sex

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
<3 years	9	1 (11)	---	---	9	1 (11)
3 to 5 years	9	0 (0)	---	---	9	0 (0)
6 to 10 years	22	2 (9)	---	---	22	2 (9)
10 + years	34	9 (27)	---	---	34	9 (27)
p-value		0.1		---		0.1

Table 126: HBV core antibody prevalence by last drug injected and duration of drug injection

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Amphetamine	9	1 (11)	46	7 (15)	55	8 (15)
Heroin	---	---	17	4 (24)	17	4 (24)
More than one	---	---	---	---	---	---
Other/not reported	--	---	2	0 (0)	2	0 (0)
p-value		---		0.6		0.6

Table 127: HBV core antibody prevalence by frequency of injection last month and duration of drug injection

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Less than daily	5	1 (20)	36	7 (19)	41	8 (20)
Daily or more	4	0 (0)	29	4 (14)	33	4 (12)
p-value		0.3		0.5		0.4

QUEENSLAND

Table 128: HBV core antibody prevalence by reuse of someone else's needle and syringe last month and duration of drug injection

Reused someone else's needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
No	5	0 (0)	29	7 (24)	34	7 (21)
Yes	1	0 (0)	9	2 (22)	10	2 (20)
p-value		---		0.9		1.0

Table 129: HBV core antibody prevalence by imprisonment last year and duration of drug injection

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
No	---	---	---	---		
Yes	9	1 (11)	65	11 (17)	74	12 (16)
p-value		---		---		---

Table 130: HBV core antibody prevalence by years spent previously in prison, sex and injector status

Years previously spent in prison	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HCBV (%)
Non-injector						
No previous imprisonment	3	0 (0)	---	---	3	0 (0)
1 year or less	38	4 (11)	---	---	38	4 (11)
> 1 to 3 years	6	1 (17)	---	---	6	1 (17)
> 3 years	7	0 (0)	---	---	7	0 (0)
p-value		0.7		---		0.7
Injector						
No previous imprisonment	---	---			---	---
1 year or less	34	4 (12)	---	---	34	4 (12)
> 1 to 3 years	13	2 (15)	---	---	13	2 (15)
> 3 years	27	6 (22)	---	---	27	6 (22)
p-value		0.5		---		0.5

Table 131: HBV core antibody prevalence by number of previous imprisonments, sex and injector status

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector						
No previous imprisonment	3	0 (0)	---	---	3	0 (0)
1 to 2	46	5 (11)	---	---	46	5 (11)
3 to 5	4	0 (0)	---	---	4	0 (0)
5 +	1	0 (0)	---	---	1	0 (0)
Not reported	1	0 (0)	---	---	1	0 (0)
p-value		0.8		---		0.8
Injector						
No previous imprisonment	---	---	---	---	---	---
1 to 2	29	1 (3)	---	---	29	1 (3)
3 to 5	36	9 (25)	---	---	36	9 (25)
5 +	9	2 (22)	---	---	9	2 (22)
p-value		0.06		---		0.06

Table 132: Prevalence of serological markers of HBV immunity from vaccination* by number of previous imprisonments, sex and injector status**

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° immune to HBV(%)	N° tested	N° immune to HBV(%)	N° tested	N° immune to HBV(%)
Non-injector						
No previous imprisonment	3	1 (33)	---	---	3	1 (33)
1 to 2	41	13 (32)	---	---	41	13 (37)
3 to 5	---	---	---	---	---	---
5 +	4	0 (0)	---	---	4	0 (0)
Not reported	1	0 (0)	---	---	1	0 (0)
p-value		0.5		---		0.5
Injector						
No previous imprisonment	---	---	---	---	---	---
1 to 2	29	12 (41)	---	---	29	8 (41)
3 to 5	27	19 (70)	---	---	27	19 (70)
5 +	8	4 (50)	---	---	8	4 (50)
p-value		0.09		---		0.09

*Cases with HBV surface antibody levels of ten or more are considered immune

**HBV core antibody positive cases have been excluded

Table 133: Self reported hepatitis B immunisation versus serology results

Self reported number of hepatitis B vaccinations received	Serological markers of immunity*					
	Male		Female		Total	
	Nº tested	Nº immune (%)	Nº tested	Nº immune (%)	Nº tested	Nº immune (%)
Nil vaccinations received	27	4 (15)	---	---	27	4 (15)
One vaccination	6	1 (17)	---	---	6	1 (17)
Two vaccinations	5	2 (40)	---	---	5	2 (40)
Three or more vaccinations	61	39 (63)	---	---	61	39 (63)
Unsure or not reported	---	---	---	---	---	---
Total	99	46 (46)	---	---	99	46 (46)
p-value		<0.001		---		<0.001

*Surface antibody levels of ≥10 are considered immune. HBV core antibody positive cases have been excluded.

QUEENSLAND

Table 134: Prevalence of serological markers of HBV immunity from vaccination* by duration of previous imprisonment, sex and injector status**

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° immune to HBV(%)	N° tested	N° immune to HBV(%)	N° tested	N° immune to HBV(%)
Non-injector						
No previous imprisonment	3	1 (33)	---	---	3	1 (33)
1 year or less	34	10 (29)	---	---	34	10 (29)
> 1 to 3 years	5	1 (20)	---	---	5	1 (20)
> 3 years	7	2 (29)	---	---	7	2 (29)
p-value		0.9				0.9
Injector						
No previous imprisonment	---	---	---	---	---	---
1 year or less	31	14 (45)	---	---	31	14 (45)
> 1 to 3 years	12	7 (58)	---	---	12	7 (58)
> 3 years	21	14 (67)	---	---	21	14 (67)
p-value		0.3		---		0.3

*Cases with HBV surface antibody levels of ten or more are considered immune

**HBV core antibody positive cases have been excluded

Table 135: HBV serology results by Indigenous status

Indigenous Status	Nº tested	Nº (%) with no evidence of immunity	Nº (%) with vaccination conferred immunity	Nº (%) immune through previous infection	Nº (%) who are HBV carriers
Non-Indigenous	117	60 (51)	43 (37)	11 (9)	3 (3)
Indigenous	14	4 (29)	8 (57)	2 (14)	0 (0)
Total	131	64 (49)	51 (39)	13 (10)	3 (2)
p-value	0.3	---	---	---	---

Table 136: HBV core antibody prevalence by Indigenous status, sex and injector status

Indigenous status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV ab (%)
Non-injector						
Non-Indigenous	48	5 (10)	---	---	48	5 (10)
Indigenous	6	0 (0)	---	---	6	0 (0)
p-value		0.4		---		0.4
Injector						
Non-Indigenous	66	10 (15)	---	---	66	10 (15)
Indigenous	8	2 (25)	---	---	8	2 (25)
p-value		0.5		---		0.5

Table 137: HBV core antibody prevalence by region/country of birth, sex and injector status

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector						
Australia	38	2 (5)	---	---	38	2 (5)
Other Oceania	8	1 (13)	---	---	8	1 (13)
Asia	2	1 (50)	---	---	2	1 (50)
UK & Ireland	2	0 (0)	---	---	2	0 (0)
Other	4	1 (25)	---	---	4	1 (25)
p-value		0.2		---		0.2
Injector						
Australia	65	10 (15)	---	---	65	10 (15)
Other Oceania	7	1 (14)	---	---	7	1 (14)
Asia	1	1 (100)	---	---	1	1 (100)
UK & Ireland	1	0 (0)	---	---	1	0 (0)
Other	---	---	---	---	---	---
p-value		0.1		---		0.1

Table 138: HBV core antibody prevalence by main language spoken at home by parents, sex and injector status

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector						
English speaking	48	3 (6)	---	---	48	3 (6)
Non-English speaking	6	2 (33)	---	---	6	2 (33)
p-value		0.03		---		0.03
Injector						
English speaking	72	11 (15)	---	---	72	11 (15)
Non-English speaking	2	1 (50)	---	---	2	1 (50)
p-value		0.2		---		0.2

Table 139 : Number (%) of respondents by demographic characteristics and sex and injector status

Demographic characteristics	Non-injector	Injector	Total
N° surveyed	15	26	41*
Sex (%)			
Male	14 (93)	22 (85)	36 (88)
Female	1 (7)	4 (15)	5 (12)
Transgender	---	---	---
Sexual identity (%)			
Heterosexual	15 (100)	25 (96)	40 (98)
Bisexual	---	1 (4)	1 (2)
Homosexual	---	---	---
Age and duration of injection (years)			
Median age	42	26	30
Age range	17-64	21-48	17-64
Age group (%)			
<25 years	3 (20)	2 (8)	5 (12)
25+ years	12 (80)	24 (92)	36 (88)
Median age 1st IDU	---	20	---
Age range	---	14-30	---
Median years IDU	---	10	---
Range	---	1-32	---
Duration of drug injection (%)			
<3 years	---	1 (4)	1 (2)
3+ years	---	23 (88)	23 (56)
Not reported	---	2 (8)	2 (5)
Aboriginal and Torres Strait Islander origin (%)			
No	9 (60)	16 (62)	25 (61)
Yes	4 (27)	2 (8)	6 (15)
Not reported	2 (13)	8 (31)	10 (24)
Region/Country of birth (%)			
Australia	13 (87)	26 (100)	39 (95)
Other Oceania	---	---	---
Asia	---	---	---
UK & Ireland	---	---	---
Other	---	---	---
Not reported	2 (13)	---	2 (5)
Main language spoken at home by parents (%)			
English speaking	13 (87)	26 (100)	39 (95)
Non-English speaking	---	---	---
Not reported	2 (13)	---	2 (5)
Imprisonment last year (%)			
No	7 (46)	12 (46)	19 (46)
Yes	4 (27)	11 (42)	15 (37)
Not reported	4 (27)	3 (12)	7 (17)
Injected in prison last month (%)			
Yes	---	1 (4)	1 (2)
No	15 (100)	25 (96)	40 (98)
Frequency of injection last month (%)			
Not last month	---	12 (46)	12 (29)
Less than weekly	---	2 (8)	2 (5)
Weekly not daily	---	6 (23)	6 (15)
Daily or more	---	5 (19)	5 (12)
Not reported	---	1 (4)	1 (2)

*Total excludes prison entrants who did not disclose injector status

Table 140: Number (%) of respondents by last drug injected and injecting behaviour in the month prior to survey

Injecting behaviour

Last drug injected (%)	**N = 26**	
Amphetamine	20	(77)
Anabolic steroids		---
Cocaine		---
Heroin	2	(8)
Heroin + Cocaine		---
Methadone		---
Morphine	3	(12)
Other	1	(4)
Places injected last month (%)**	**N = 14**	
Prison	1	(8)
Own home	11	(79)
Friend's home	7	(50)
Dealer's home	2	(14)
Street, park, beach	2	(14)
Car	7	(50)
Public toilet	4	(29)
Shooting room		---
MSIC*		---
Squat		---
Train, bus or cab		---
Use of new sterile needles & syringes last month (%)	**N = 14**	
All injections	12	(86)
Most of the time	1	(7)
Half of the time	1	(7)
Some of the time		---
Not last month		---

*Medically Supervised Injecting Centre
** More than one option could be selected

Re-used someone else's needle & syringe last month (%)		
None	12	(86)
Once	1	(7)
Twice	1	(7)
3 - 5 times		---
More than five		---
Number of people needle & syringe was re-used after last month (%)		
None	12	(86)
One	1	(7)
Two		---
Three to five		---
More than five		---
Not reported	1	(7)
Relationship to people needle & syringe was re-used after last month (%) **		
Regular sex partner	1	(50)
Casual sex partner		---
Close friend		---
Acquaintance	1	(50)
Stranger		---
Family		---
Brother		---
Equipment used after someone else last month (%)**	**N = 9**	
Spoon	1	(7)
Water	4	(29)
Filter	2	(14)
Tourniquet	1	(7)
Drug mix	1	(7)
Injected by someone after that person injected themselves or others last month (%)	**N = 14**	
No	11	(79)
Yes	3	(21)

Table 141: Number (%) of respondents by treatment for drug use and injector status

	Non-injector		Injector		Total	
Nº Surveyed	N = 15		N = 26		N = 41	
Any treatment/therapy for drug use (%)						
No	14	(93)	10	(38)	24	(59)
Yes	---	---	16	(62)	16	(39)
Not reported	1	(7)		---	1	(2)
History of methadone treatment (%)						
Currently	---	---	3	(12)	3	(7)
Previously	---	---	6	(23)	6	(15)
Never	14	(93)	16	(62)	30	(73)
Not reported	1	(7)	1	(4)	2	(5)
History of other pharmacotherapy treatment (%)						
Currently		---	2	(8)	2	(5)
Previously		---	2	(8)	2	(5)
Never	14	(93)	21	(81)	35	(85)
Not reported	1	(7)	1	(4)	2	(5)

Table 142: Number (%) of respondents by site of needle and syringe acquisition last month

Needle and syringe acquisition		
Nº surveyed	**N = 14**	
From an NSP last month (%)		
Daily or almost daily	2	(14)
A couple of times each week	2	(14)
Less than weekly	4	(29)
Once last month		---
Not in the last month	4	(29)
Not reported	2	(14)
From a chemist last month (%)		
Daily or almost daily	2	(14)
A couple of times each week	1	(7)
Less than weekly	1	(7)
Once last month	6	(43)
Not in the last month	4	(29)

Table 143: Number (%) of respondents by sexual behaviour in the month prior to survey and injector status

Sexual Behaviour	Non-injector		Injector		Total	
Nº surveyed	N = 15		N = 26		N = 41	
Sex last month (%)						
No	8	(53)	9	(35)	17	(41)
Yes	7	(47)	17	(65)	24	(59)
Condom use at last sex (%)						
No	10	(67)	22	(85)	32	(78)
Yes	5	(33)	4	(15)	9	(22)
Condom use with regular sex partner(s) last month (%)*						
No	4	(57)	9	(90)	13	(76)
Sometimes	1	(14)	1	(10)	2	(12)
Always	2	(29)	---		2	(12)
Condom use with new sex partner(s) last month (%)*						
No	---		1	(50)	1	(50)
Sometimes	---		1	(50)	1	(50)
Always	---		---		---	
Condom use with casual sex partner(s) last month (%)*						
No	---		5	(71)	5	(71)
Sometimes	---		2	(29)	2	(29)
Always	---		---		---	
Duration of regular sexual relationship (%)*						
One month	---		---		---	
2 – 6 months	---		---		---	
6 – 12 months	1	(13)	---		1	(6)
> 12 months	4	(50)	5	(56)	9	(53)
Not reported	3	(38)	4	(44)	7	(41)
Sex work last month (%)**						
No	15	(100)	25	(96)	40	(98)
Yes	---		1	(4)	1	(2)
Condom used at last sex work last month (%)**						
No	---		---		---	
Yes	---		1	(100)	1	(100)

*Percentages exclude missing data and participants reporting no regular, new or casual sex partners respectively in the previous month

**Percentages exclude missing data

Table 144: Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, Hepatitis B vaccination and treatment for HCV by injector status

	Non-injector	Injector	Total
N° surveyed	N = 15	N = 26	N = 41
Previous HIV test (%)			
Yes, last year	5 (33)	13 (50)	18 (44)
> 1 year ago	4 (27)	8 (31)	12 (29)
Never tested	5 (33)	5 (19)	10 (24)
Not reported	1 (7)	---	1 (2)
HBV infection (%)			
No	14 (93)	19 (73)	33 (80)
Yes	---	6 (23)	6 (15)
Don't know	1 (7)	1 (4)	2 (5)
Hepatitis B vaccination (%)	N = 15	N = 20	N = 35
No	11 (73)	7 (35)	18 (51)
Yes	4 (27)	11 (55)	15 (43)
Don't know	---	2 (10)	2 (6)
Previous HCV test (%)			
Yes, last year	4 (27)	9 (35)	13 (32)
> 1 year ago	3 (20)	11 (42)	14 (34)
Never tested	8 (53)	6 (23)	14 (34)
Any treatment for HCV (%)**	N = 1	N = 12	N = 13
Interferon	---	---	---
Interferon & Ribavirin	1 (100)	---	1 (8)
Pegasys & Ribavirin	---	---	---
Other	---	---	---
No treatment	---	12 (100)	12 (100)
Current treatment for HCV			
Interferon	---	---	---
Interferon & Ribavirin	---	---	---
Other	---	---	---

*Participants who reported a previous HBV infection have been excluded.

**Participants who did not self-report being HCV antibody positive have been excluded.

Table 145: HIV antibody prevalence by sex and injector status

	Male		Female		Total	
Injector status	**N° tested**	**N° with HIV (%)**	**N° tested**	**N° with HIV (%)**	**N° tested**	**N° with HIV (%)**
Non-injector	8	0 (0)		---	8	0 (0)
Injector	15	0 (0)	2	0 (0)	17	0 (0)
p-value		---		---		---

Table 146: HCV antibody prevalence by sex and injector status

Injector status	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector	9	1 (11)	---	---	9	1 (11)
Injector	16	10 (63)	2	2 (100)	18	12 (67)
p-value		0.01		---		0.01

Table 147: HCV antibody prevalence by sexual identity, sex and injector status

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
Heterosexual	9	1 (11)	---	---	9	1 (11)
Bisexual	---	---	---	---	---	---
Homosexual	---	---	---	---	---	---
p-value		---		---		---
Injector						
Heterosexual	16	10 (63)	1	1 (100)	17	11 (65)
Bisexual	---	---	1	1 (100)	1	1 (100)
Homosexual	---	---	---	---	---	---
p-value		---		---		0.5

Table 148: HCV antibody prevalence by age group, sex and injector status

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
< 20 years	---	---	---	---	---	---
20 – 24	1	0 (0)	---	---	1	0 (0)
25 – 29	1	0 (0)	---	---	1	0 (0)
30 + years	7	1 (14)	---	---	7	1 (14)
p-value		0.9		---		0.9
Injector						
< 20 years	---	---	---	---	---	---
20 – 24	---	---	---	---	---	---
25 – 29	7	1 (14)	2	2 (100)	9	4 (44)
30 + years	9	9 (100)	---	---	9	8 (89)
p-value		0.01		---		0.05

Table 149: HCV antibody prevalence by duration of drug injection and sex

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<3 years	---	---	---	---	---	---
3 to 5 years	---	---	---	---	---	---
6 to 10 years	6	2 (33)	1	1 (100)	7	3 (43)
10 + years	9	8 (89)	1	1 (100)	10	9 (90)
p-value		0.04		---		0.04

Table 150: HCV antibody prevalence by last drug injected and duration of drug injection

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Amphetamine	---	---	9	6 (67)	9	6 (67)
Heroin	---	---	1	1 (100)	1	1 (100)
More than one	---	---	3	2 (67)	3	2 (67)
Other/not reported	---	---	4	3 (75)	4	3 (75)
p-value		---		0.9		0.9

Table 151: HCV antibody prevalence by frequency of injection last month and duration of drug injection

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Less than daily	---	---	12	7 (58)	12	7 (58)
Daily or more	---	---	4	1 (25)	4	1 (25)
Not reported	---	---	1	1 (100)	1	1 (100)
p-value		---		0.2		0.2

Table 152: HCV antibody prevalence by reuse of someone else's needle and syringe last month and duration of drug injection

Reused someone else's needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
No	---	---	8	6 (75)	8	6 (75)
Yes	---	---	2	2 (100)	2	2 (100)
p-value		---		0.4		0.4

Table 153: HCV antibody prevalence by imprisonment last year and duration of drug injection

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
No	---	---	8	6 (75)	8	6 (75)
Yes	---	---	6	4 (67)	6	4 (67)
p-value		---		0.7		0.7

Table 154: HCV antibody prevalence by years spent previously in prison, sex and injector status

Years spent previously in prison	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
No previous imprisonment	4	0 (0)	---	---	4	0 (0)
1 year or less	3	1 (33)	---	---	3	1 (33)
> 1 to 3 years	2	0 (0)	---	---	2	0 (0)
> 3 years	---	---	---	---	---	---
p-value		0.3		---		0.3
Injector						
No previous imprisonment	6	4 (67)	---	---	6	4 (67)
1 year or less	4	1 (25)	---	---	4	1 (25)
> 1 to 3 years	3	3 (100)	2	2 (100)	5	5 (100)
> 3 years	3	2 (67)	---	---	3	2 (67)
p-value		0.2		---		0.1

Table 155: HCV antibody prevalence by number of previous imprisonments, sex and injector status

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
No previous imprisonment	4	0 (0)	---	---	4	0 (0)
1 to 2	1	1 (100)	---	---	1	1 (100)
3 to 5	3	0 (0)	---	---	3	0 (0)
5 +	---	---	---	---	---	---
Not reported	1	0 (0)	---	---	1	0 (0)
p-value		0.03		---		0.03
Injector						
No previous imprisonment	6	4 (67)	---	---	6	4 (67)
1 to 2	4	2 (50)	---	---	4	2 (50)
3 to 5	1	1 (100)	---	---	1	1 (100)
5 +	4	3 (75)	2	2 (100)	6	5 (83)
Not reported	1	0 (0)	---	---	1	0 (0)
p-value		0.6		---		0.4

Table 156: Self-reported exposure to HCV versus serology by sex and injector status

	Hepatitis C serology*					
	Male		Female		Total	
Self-report HCV	N° tested	N° with HCV(%)	N° tested	N° with HCV(%)	N° tested	N° with HBV(%)
Non-injector						
Positive	1	1 (100)	---	---	1	1 (100)
Negative	2	0 (0)	---	---	2	0 (0)
Not sure	1	0 (0)	---	---	1	0 (0)
p-value		0.03		---		0.03
Injector						
Positive	7	7 (100)	2	2 (100)	9	9 (100)
Negative	5	2 (40)	---	---	5	2 (40)
Not sure	1	1 (1)	---	---	1	1 (100)
p-value		0.01		---		0.006

*Cases positive for HCV antibody

Table 157: HCV antibody prevalence by Indigenous status, sex and injector status

	Male		Female		Total	
Indigenous Status	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
Non-Indigenous	5	0 (0)	---	---	5	0 (0)
Indigenous	2	0 (0)	---	---	2	0 (0)
Not reported	2	1 (50)	---	---	2	1 (50)
p-value		0.1		---		0.1
Injector						
Non-Indigenous	10	8 (80)	1	1 (100)	11	9 (81)
Indigenous	1	1 (100)	---	---	1	1 (100)
Not reported	5	1 (20)	1	1 (100)	6	2 (33)
p-value		0.06		---		0.1

Table 158: HCV antibody prevalence by region/country of birth, sex and injector status

	Male		Female		Total	
Region/Country of birth	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
Australia	9	1 (11)	---	---	9	1 (11)
Other Oceania	---	---	---	---	---	---
Asia	---	---	---	---	---	---
UK & Ireland	---	---	---	---	---	---
Other	---	---	---	---	---	---
p-value		---		---		---
Injector						
Australia	16	10 (63)	2	2 (100)	18	12 (67)
Other Oceania	---	---	---	---	---	---
Asia	---	---	---	---	---	---
UK & Ireland	---	---	---	---	---	---
Other	---	---	---	---	---	---
p-value		---		---		---

Table 159: HCV antibody prevalence by main language spoken at home by parents, sex and injector status

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
English speaking	9	1 (11)	---	---	9	1 (11)
Non-English speaking	---	---	---	---	---	---
p-value		---		---	---	---
Injector						
English speaking	16	10 (63)	2	2 (100)	18	12 (67)
Non-English speaking	---	---		---	---	---
p-value		---		---		---

Table 160: HBV surface antigen prevalence by sex and injector status

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector	8	0 (0)	---	---	8	0 (0)
Injector	15	0 (0)	3	1 (33)	18	1 (6)
p- value		---		---		0.5

Table 161: HBV core antibody prevalence by sex and injector status

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector	9	0 (0)	0	0 (0)	9	0 (0)
Injector	16	6 (38)	3	2 (67)	19	8 (42)
p-value		0.04		---		0.02

Table 162: HBV core antibody prevalence by sexual identity sex and injector status

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector						
Heterosexual	9	0 (0)	---	---	9	0 (0)
Bisexual	---	---	---	---	---	---
Homosexual	---	---	---	---	---	---
p-value		---		---		---
Injector						
Heterosexual	16	6 (38)	2	2 (100)	18	8 (44)
Bisexual	---	---	1	0 (0)	1	0 (0)
Homosexual	---	---	---	---		---
p-value		---		0.1		0.4

Table 163: HBV core antibody prevalence by age group, sex and injector status

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector						
< 20 years	---	---	---	---	---	---
20 – 24	1	0 (0)	---	---	1	0 (0)
25 – 29	1	0 (0)	---	---	1	0 (0)
30 + years	7	0 (0)	---	---	7	0 (0)
p-value		---		---		---
Injector						
< 20 years	---	---	---	---	---	---
20 – 24	---	---	1	1 (100)	1	1 (100)
25 – 29	7	3 (43)	2	1 (50)	9	4 (44)
30 + years	9	3 (33)	---	---	9	3 (33)
p-value		0.7		0.4		0.4

Table 164: HBV core antibody prevalence by duration of drug injection and sex

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
<3 years	---	---	---	---	---	---
3 to 5 years	---	---	1	1 (100)	1	1 (100)
6 to 10 years	6	1 (17)	1	1 (100)	7	2 (29)
10 + years	9	4 (44)	1	0 (0)	10	4 (40)
Not reported	1	1 (100)	---	---	1	1 (100)
p-value		0.2		0.2		0.3

Table 165: HBV core antibody prevalence by last drug injected and duration of drug injection

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Amphetamine	---	---	10	5 (50)	10	5 (50)
Heroin	---	---	1	0 (0)	1	0 (0)
More than one	---	---	3	0 (0)	3	0 (0)
Other/not reported	---	---	4	2 (50)	4	2 (50)
p-value		---		0.4		0.4

Table 166: HBV core antibody prevalence by frequency of injection last month and duration of drug injection

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Less than daily	---	---	13	4 (31)	13	4 (31)
Daily or more	---	---	4	3 (75)	4	3 (75)
Not reported	---	---	1	0 (0)	1	0 (0)
p-value		---		0.2		0.2

Table 167: HBV core antibody prevalence by reuse of someone else's needle and syringe last month and duration of drug injection

Reused someone else's needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
No	---	---	9	4 (44)	9	4 (44)
Yes	---	---	2	0 (0)	2	0 (0)
p-value		---		0.2		0.2

Table 168: HBV core antibody prevalence by imprisonment last year and duration of drug injection

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
No	---	---	8	3 (38)	8	3 (38)
Yes	---	---	7	2 (29)	7	2 (29)
p-value		---		0.7		0.7

Table 169: HBV core antibody prevalence by years spent previously in prison, sex and injector status

Years spent previously in prison	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HCBV (%)
Non-injector						
No previous imprisonment	4	0 (0)	---	---	4	0 (0)
1 year or less	3	0 (0)	---	---	3	0 (0)
> 1 to 3 years	2	0 (0)	---	---	2	0 (0)
> 3 years	---	---	---	---	---	---
p-value		---		---		---
Injector						
No previous imprisonment	6	3 (50)	---	---	6	3 (50)
1 year or less	4	1 (25)	1	1 (100)	5	2 (40)
> 1 to 3 years	3	1 (33)	2	1 (50)	5	2 (40)
> 3 years	3	1 (33)	---	---	3	1 (33)
p-value		0.9		0.4		1.0

Table 170: HBV core antibody prevalence by number of previous imprisonments, sex and injector status

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector						
No previous imprisonment	4	0 (0)	---	---	4	0 (0)
1 to 2	1	0 (0)	---	---	1	0 (0)
3 to 5	3	0 (0)	---	---	3	0 (0)
5 +	---	---	---	---	---	---
Not reported	1	0 (0)	---	---	1	0 (0)
p-value		---		---		---
Injector						
No previous imprisonment	6	3 (50)	---	---	6	3 (50)
1 to 2	4	1 (25)	---	---	4	1 (25)
3 to 5	1	0 (0)	1	1 (100)	2	1 (1)
5 +	4	1 (25)	2	1 (50)	6	2 (33)
Not reported	1	1 (100)	---	---	1	1 (100)
p-value		0.5		0.4		0.7

Table 171: Self reported hepatitis B immunisation versus serology results

Self reported number of hepatitis B vaccinations received	Serological markers of immunity*					
	Male		Female		Total	
	Nº tested	Nº immune (%)	Nº tested	Nº immune (%)	Nº tested	Nº immune (%)
Nil vaccinations received	9	0 (0)	---	---	9	0 (0)
One vaccination	---	---	---	---	---	---
Two vaccinations	2	0 (0)	---		2	0 (0)
Three or more vaccinations	7	5 (71)	1	0 (0)	8	5 (63)
Unsure or not reported	1	0 (0)	---	---	1	0 (0)
Total	19	5 (26)	1	0 (0)	19	5 (26)
p-value		0.01		---		0.01

*Surface antibody levels of $\geq$10 are considered immune. HBV core antibody positive cases have been excluded.

Table 172: Prevalence of serological markers of HBV immunity from vaccination* by number of previous imprisonments, sex and injector status**

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° immune to HBV(%)	N° tested	N° immune to HBV(%)	N° tested	N° immune to HBV(%)
Non-injector						
No previous imprisonment	4	1 (25)	---	---	4	1 (25)
1 to 2	1	0 (0)	---	---	1	0 (0)
3 to 5	3	0 (0)	---	---	3	0 (0)
5 +	---	---	---	---	---	---
Not reported	1	0 (0)	---	---	1	0 (0)
p-value		0.7		---		0.7
Injector						
No previous imprisonment	3	1 (33)	---	---	3	1 (33)
1 to 2	3	0 (0)	---	---	3	0 (0)
3 to 5	1	0 (0)	---	---	1	0 (0)
5 +	4	1 (100)	1	0 (0)	5	4 (80)
p-value		0.04		---		0.01

*Cases with HBV surface antibody levels of ten or more are considered to be immune

**HBV core antibody positive cases have been excluded

Table 173: Prevalence of serological markers of HBV immunity from vaccination* by years spent previously in prison, sex and injector status**

Years spent previously in prison	Male		Female		Total	
	N° tested	N° immune to HBV(%)	N° tested	N° immune to HBV(%)	N° tested	N° immune to HBV(%)
Non-injector						
No previous imprisonment	4	1 (25)	---	---	4	1 (25)
1 year or less	3	0 (0)	---	---	2	0 (0)
> 1 to 3 years	2	0 (0)	---	---	2	0 (0)
> 3 years	---	---	---	---	---	---
p-value		0.5		---		0.5
Injector						
No previous imprisonment	3	1 (33)	---	---	3	1 (33)
1 year or less	3	0 (0)	---	---	3	0 (0)
> 1 to 3 years	2	1 (50)	1	0 (0)	3	1 (50)
> 3 years	3	3 (100)	---	---	3	3 (100)
p-value		0.1		---		0.1

*Cases with HBV surface antibody levels of ten or more are considered to be immune

**HBV core antibody positive cases have been excluded

Table 174: Self-reported exposure to HBV versus serology by sex and injector status

	Hepatitis B serology*					
	Male		Female		Total	
Self-report HBV	N° tested	N° with HBV(%)	N° tested	N° with HBV(%)	N° tested	N° with HBV(%)
Non-injector						
Yes	---	---	---	---	---	---
No	8	0 (0)	---	---	8	0 (0)
Not sure	1	0 (0)	---	---	1	0 (0)
p-value		---		---		---
Injector						
Yes	5	5 (100)	1	1 (100)	6	6 (100)
No	10	1 (10)	2	1 (50)	12	2 (17)
Not sure	1	0 (0)	---	---	1	0 (0)
p-value		0.002		0.4		0.002

*Cases positive for HBV core antibody

Table 175: HBV serology results by Indigenous status

Indigenous Status	Nº tested	Nº (%) with no evidence of immunity	Nº (%) with vaccination conferred immunity	Nº (%) immune through previous infection	Nº (%) who are HBV carriers
Non-Indigenous	18	9 (50)	4 (22)	4 (22)	1 (6)
Indigenous	3	2 (67)	0 (0)	1 (33)	0 (0)
Total	21	11 (52)	4 (19)	5 (24)	1 (5)
p-value	0.7	---	---	---	---

Table 176: HBV core antibody prevalence by Indigenous status, sex and injector status

	Male		Female		Total	
Indigenous status	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector						
Non-Indigenous	5	0 (0)	---	---	5	0 (0)
Indigenous	2	0 (0)	---	---	2	0 (0)
Not reported	2	1 (50)	---	---	2	1 (50)
p-value		0.1		---		0.1
Injector						
Non-Indigenous	10	8 (80)	1	1 (100)	11	9 (82)
Indigenous	1	1 (100)	---	---	1	1 (100)
Not reported	5	1 (20)	1	1 (100)	6	2 (33)
p-value		0.06		---		0.1

Table 177: HBV core antibody prevalence by region/country of birth, sex and injector status

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector						
Australia	9	1 (11)	---	---	9	1 (11)
Other Oceania	---	---	---	---	---	---
Asia	---	---	---	---	---	---
UK & Ireland	---	---	---	---	---	---
Other	---	---	---	---	---	---
p-value		---		---		---
Injector						
Australia	16	10 (63)	2	2 (100)	18	12 (67)
Other Oceania	---	---	---	---	---	---
Asia	---	---	---	---	---	---
UK & Ireland	---	---	---	---	---	---
Other	---	---	---	---	---	---
p-value		---		---		---

Table 178: HBV core antibody prevalence by main language spoken at home by parents sex and injector status

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector						
English speaking	9	1 (11)	---	---	9	1 (11)
Non-English speaking	---	---	---	---	---	---
p-value		---		---		---
Injector						
English speaking	16	10 (63)	2	2 (100)	18	12 (67)
Non-English speaking	---	---	---	---	---	---
p-value		---		---		---

Table 179 : Number (%) of respondents by demographic characteristics and sex and injector status

Demographic characteristics	Non-injector	Injector	Total
N^{o} surveyed	47	66	113*
Sex (%)			
Male	38 (81)	51 (77)	89 (79)
Female	9 (19)	15 (23)	24 (21)
Transgender	---	---	---
Sexual identity (%)			
Heterosexual	46 (98)	64 (97)	110 (97)
Bisexual	---	2 (3)	2 (2)
Homosexual	1 (2)	---	1 (1)
Age and duration of injection (years)			
Median age	30	30	30
Age range	18-60	27-35	18-60
Age group (%)			
<25 years	15 (32)	18 (27)	33 (29)
25+ years	32 (68)	43 (65)	75 (66)
Not reported	---	5 (8)	5 (4)
Median age 1st IDU	---	19	---
Age range	---	10 - 39	---
Median years IDU	---	8	---
Range	---	<1 - 26	---
Duration of drug injection (%)			
<3 years	---	10 (15)	10 (9)
3+ years	---	52 (84)	52 (46)
Not reported		4 (6)	4 (4)
Aboriginal and Torres Strait Islander origin (%)			
No	30 (64)	40 (61)	70 (62)
Yes	17 (36)	26 (39)	43 (38)
Region / Country of birth (%)			
Australia	42 (89)	57 (86)	99 (88)
Other Oceania	1 (2)	1 (2)	2 (2)
Asia	1 (2)	---	1 (1)
UK & Ireland	1 (2)	4 (6)	5 (4)
Other	2 (4)	3 (5)	5 (4)
Not reported	---	1 (2)	1 (1)
Main language spoken at home by parents (%)			
English speaking	44 (94)	64 (97)	108 (96)
Non-English speaking	3 (6)	1 (2)	4 (4)
Not reported	---	1 (2)	---
Imprisonment last year (%)			
No	28 (60)	31 (47)	59 (52)
Yes	14 (30)	30 (45)	44 (39)
Not reported	5 (10)	5 (8)	10 (9)
Injected in prison last month (%)			
Yes	---	1 (2)	1 (<1)
No	47 (100)	65 (98)	112 (99)
Frequency of injection last month (%)			
Not last month	---	26 (39)	26 (23)
Less than weekly	---	10 (15)	10 (9)
Weekly not daily	---	1 (2)	1 (<1)
Daily or more	---	29 (44)	29 (26)

*Total excludes prison entrants who did not disclose injector status

WESTERN AUSTRALIA

Table 180: Number (%) of respondents by last drug injected and injecting behaviour in the month prior to survey

Injecting behaviour

Last drug injected (%)	**N = 66**	
Amphetamine	54	(82)
Anabolic steroids		---
Cocaine		---
Heroin	7	(10)
Heroin + Cocaine		---
Methadone		---
Morphine	3	(5)
Other	2	(3)
Places injected last month (%)**	**N= 40**	
Prison	1	(3)
Own home	26	(65)
Friend's home	19	(48)
Dealer's home	5	(13)
Street, park, beach	6	(15)
Car	7	(18)
Public toilet	2	(5)
Shooting room		---
MSIC*		---
Squat		---
Train, bus or cab		---
Not reported	3	(8)
Use of new sterile needles & syringes last month (%)		
All injections	25	(63)
Most of the time	9	(23)
Half of the time	1	(3)
Some of the time	4	(10)
Not last month		---
Not reported	1	(3)

* Medically Supervised Injecting Centre

Re-used someone else's needle & syringe last month (%)		
None	29	(73)
Once		---
Twice	6	(15)
3 - 5 times	1	(3)
More than five	2	(5)
Not reported	2	(4)
Number of people needle & syringe was re-used with after last month (%)		
None	29	(72)
One	3	(8)
Two	3	(8)
Three to five	1	(3)
More than five	2	(5)
Not reported	2	(5)
Relationship to people needle & syringe was re-used after last month (%) **		
Regular sex partner	5	(13)
Casual sex partner		---
Close friend	2	(15)
Acquaintance		---
Stranger		---
Family	2	(18)
Brother	1	(9)
Other/ not specified	1	(9)
Equipment used after someone else last month (%)**		
Spoon	9	(5)
Water	8	(3)
Filter	7	(3)
Tourniquet	5	(45)
Drug mix	7	(64)
Injected by someone after that person injected themselves or others last month (%)		
No		---
Yes	4	(36)
Not reported	7	(64)

** More than one option could be selected

Table 181: Number (%) of respondents by treatment for drug use and injector status

	Non-injector		Injector		Total	
Nº Surveyed	47		66		113	
Any treatment/therapy for drug use (%)						
No	41	(87)	41	(62)	82	(73)
Yes	6	(13)	25	(38)	31	(27)
History of methadone treatment (%)						
Currently	1	(2)	3	(5)	4	(4)
Previously	---	---	3	(5)	3	(3)
Never	45	(96)	60	(91)	105	(93)
Not reported	1	(2)		---	1	(<1)
History of other pharmacotherapy treatment (%)						
Currently	1	(2)	4	(6)	5	(4)
Previously		---	4	(6)	4	(4)
Never	45	(96)	58	(88)	103	(92)
Not reported	1	(2)		---	1	(<1)

Table 182: Number (%) of respondents by site of needle and syringe acquisition last month

Needle and syringe acquisition		
Nº surveyed	**N = 40**	
From an NSP last month (%)		
Daily or almost daily	3	(8)
A couple of times each week	5	(13)
Less than weekly	7	(18)
Once last month	5	(13)
Not in the last month	18	(45)
Not reported	2	(5)
From a chemist last month (%)		
Daily or almost daily	6	(15)
A couple of times each week	6	(15)
Less than weekly	8	(20)
Once last month	6	(15)
Not in the last month	13	(33)
Not reported	1	(3)

Table 183: Number (%) of respondents by sexual behaviour in the month prior to survey and injector status

Sexual Behaviour	Non-injector		Injector		Total	
Nº surveyed	N = 47		N = 66		N = 113	
Sex last month (%)						
No	14	(30)	24	(36)	38	(34)
Yes	32	(68)	41	(62)	73	(65)
Not reported	1	(2)	1	(2)	2	(2)
Condom use at last sex (%)						
No	36	(77)	46	(70)	82	(73)
Yes	11	(23)	20	(30)	31	(27)
Condom use with regular sex partner(s) last month (%)*						
No	22	(88)	21	(75)	43	(81)
Sometimes	2	(8)	2	(7)	4	(8)
Always	1	(4)	5	(18)	6	(11)
Condom use with new sex partner(s) last month (%)*						
No	5	(63)	12	(71)	17	(68)
Sometimes	2	(25)	1	(6)	3	(12)
Always	1	(13)	4	(24)	5	(20)
Condom use with casual sex partner(s) last month (%)*						
No	7	(78)	9	(69)	16	(73)
Sometimes	2	(22)	1	(8)	3	(14)
Always		---	3	(23)	3	(14)
Duration of regular sexual relationship (%)*						
One month		---	1	(3)	1	(2)
2 - 6 months	3	(10)	1	(3)	4	(6)
6 - 12 months	5	(17)	4	(11)	9	(14)
> 12 months	13	(45)	19	(53)	32	(49)
Not reported	8	(28)	11	(31)	19	(29)
Sex work last month (%)**						
No	46	(98)	65	(100)	111	(99)
Yes	1	(2)		---	1	(1)
Condom used at last sex work last month (%)**						
No		---		---		---
Yes	1	(100)		---	1	(100)

*Percentages exclude missing data and participants reporting no regular, new or casual sex partners respectively in the previous month

* *Percentages exclude missing data

Table 184: Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, Hepatitis B vaccination and treatment for HCV by injector status

	Non-injector	Injector	Total
N° surveyed	N = 47	N = 66	N = 113
Previous HIV test (%)			
Yes, last year	8 (17)	26 (39)	34 (30)
> 1 year ago	11 (23)	17 (26)	28 (25)
Never tested	27 (57)	23 (35)	50 (44)
Not reported	1 (2)	---	1 (<1)
HBV infection (%)			
No	41 (87)	52 (79)	93 (82)
Yes	1 (2)	5 (8)	6 (5)
Don't know	5 (11)	9 (14)	14 (12)
Hepatitis B vaccination (%)*	N = 46	N = 61	N = 107
No	21 (46)	19 (31)	40 (37)
Yes	12 (26)	31 (51)	43 (40)
Don't know	12 (26)	11 (18)	23 (22)
Not reported	1 (2)	---	1 (<1)
Previous HCV test (%)			
Yes, last year	6 (13)	31 (47)	37 (33)
> 1 year ago	7 (15)	12 (18)	19 (17)
Never tested	33 (72)	23 (35)	56 (50)
Not reported	1 (2)	---	1 (<1)
Any treatment for HCV (%)**		N = 16	N = 16
Interferon	---	1 (6)	1 (<1)
Interferon & Ribavirin	---	---	---
Pegasys & Ribavirin	---	---	---
Other	---	---	---
No treatment	---	---	---
Current treatment for HCV			
Interferon	---	---	---
Interferon & Ribavirin	---	---	---
Other	---	---	---

* Participants who reported a previous HBV infection have been excluded.

Table 185: HIV antibody prevalence by sex and injector status

	Male		Female		Total	
Injector status	**N° tested**	**N° with HIV (%)**	**N° tested**	**N° with HIV (%)**	**N° tested**	**N° with HIV (%)**
Non-injector	36	0 (0)	7	0 (0)	43	0 (0)
Injector	43	0 (0)	5	0 (0)	48	0 (0)
p-value		---		---		---

Table 186: HCV antibody prevalence by sex and injector status

Injector status	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector	36	2 (6)	7	0 (0)	43	2 (5)
Injector	43	12 (28)	5	4 (80)	48	16 (33)
p-value		0.01		0.004		0.001

Table 187: HCV antibody prevalence by sexual identity, sex and injector status

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
Heterosexual	36	2 (6)	7	0 (0)	43	2 (5)
Bisexual	---	---	---	---	---	---
Homosexual	---	---	---	---	---	---
p-value		---		---		---
Injector						
Heterosexual	43	12 (28)	5	4 (80)	48	16 (33)
Bisexual	---	---	---	---	---	---
Homosexual	---	---	---	---	---	---
p-value		---		---		---

Table 188: HCV antibody prevalence by age group, sex and injector status

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
< 20 years	7	0 (0)	---	---	7	0 (0)
20 – 24	7	1 (14)	1	0 (0)	8	1 (13)
25 – 29	7	0 (0)	1	0 (0)	8	0 (0)
30 + years	15	1 (7)	5	0 (0)	20	1 (5)
p-value		0.6		---		0.6
Injector						
< 20 years	4	1 (25)		---	4	1 (25)
20 – 24	11	1 (9)		---	11	1 (9)
25 – 29	9	1 (11)	2	2 (100)	11	3 (27)
30 + years	19	9 (47)	3	2 (67)	22	11 (50)
p-value		0.08		0.3		0.1

Table 189: HCV antibody prevalence by duration of drug injection and sex

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
<3 years	9	0 (0)	---	---	9	0 (0)
3 to 5 years	5	3 (60)	---	---	5	3 (60)
6 to 10 years	12	2 (17)	1	1 (100)	13	3 (23)
10 + years	16	7 (44)	2	1 (50)	18	8 (44)
Not reported	1	0 (0)	2	2 (100)	3	2 (67)
p-value		0.06		0.4		0.06

Table 190: HCV antibody prevalence by last drug injected and duration of drug injection

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Amphetamine	8	---	32	13 (41)	41*	13 (32)
Heroin	---	---	---	---	---	---
More than one	1	---	3	2 (67)	4	2 (50)
Other/not reported	---	---	3	1 (33)	3	1 (33)
p-value		---		0.6		0.8

* Total includes those who did not report duration of drug injection

Table 191: HCV antibody prevalence by frequency of injection last month and duration of drug injection

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Less than daily	5	0 (0)	23	7 (30)	28	7 (25)
Daily or more	4	0 (0)	15	9 (60)	20*	9 (45)
p-value		---		0.8		0.1

*Total includes those who did not report duration of drug injection

Table 192: HCV antibody prevalence by reuse of someone else's needle and syringe last month and duration of drug injection

Reused someone else's needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
No	6	0 (0)	13	8 (62)	19	8 (42)
Yes	1	0 (0)	5	3 (60)	7*	3 (43)
p-value		---		1.0		1.0

*Total includes those who did not report duration of drug injection

Table 193: HCV antibody prevalence by imprisonment last year and duration of drug injection

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
No	6	0 (0)	18	5 (28)	24	5 (21)
Yes	3	0 (0)	18	10 (56)	21	10 (48)
p-value		---		1.0		0.06

Table 194: HCV antibody prevalence by years spent previously in prison, sex and injector status

Years spent previously in prison	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
No previous imprisonment	13	0 (0)	5	0 (0)	18	0 (0)
1 year or less	13	1 (8)	2	0 (0)	15	1 (7)
> 1 to 3 years	7	1 (14)	---	---	7	1 (14)
> 3 years	2	0 (0)	---	---	2	0 (0)
Not reported	1	0 (0)	---	---	1	0 (0)
p-value		0.7		---		0.6
Injector						
No previous imprisonment	15	0 (0)	1	0 (0)	16	0 (0)
1 year or less	15	4 (27)	2	2 (100)	17	6 (35)
> 1 to 3 years	5	2 (40)	2	2 (100)	7	4 (57)
> 3 years	8	6 (75)	---	---	8	6 (75)
p-value		0.002		---		0.001

Table 195: HCV antibody prevalence by number of previous imprisonments, sex and injector status

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
No previous imprisonment	13	0 (0)	4	0 (0)	17	0 (0)
1 to 2	12	1 (8)	2	0 (0)	14	1 (7)
3 to 5	7	1 (14)	1	0 (0)	8	1 (13)
5 +	1	0 (0)	---	---	1	0 (0)
Not reported	3	0 (0)	---	---	3	0 (0)
p-value		0.7		---		0.7
Injector						
No previous imprisonment	15	0 (0)	1	0 (0)	16	0 (0)
1 to 2	8	4 (50)	3	3 (100)	11	7 (64)
3 to 5	12	4 (33)	1	1 (100)	13	5 (39)
5 +	7	4 (57)	---	---	7	4 (57)
Not reported	1	0 (0)	---	---	1	0 (0)
p-value		0.02		0.1		0.005

Table 196: Self-reported exposure to HCV versus serology by sex and injector status

Self-report HCV	Hepatitis C serology*					
	Male		Female		Total	
	N° tested	N° with HCV(%)	N° tested	N° with HCV(%)	N° tested	N° with HBV(%)
Non-injector						
Positive	---	---	---	---	---	---
Negative	6	1 (17)	3	0 (0)	9	1 (11)
Not sure	2	1 (50)	---	---	2	1 (50)
p-value		0.3		---		0.2
Injector						
Positive	6	6 (100)	2	2 (100)	8	8 (100)
Negative	19	5 (26)	---	---	19	5 (26)
Not sure	---	---	1	1 (100)	1	1 (100)
p-value		0.002		---		0.001

*Cases positive for HCV antibody

Table 197: HCV antibody prevalence by Indigenous status, sex and injector status

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
No	22	1 (5)	4	0 (0)	26	1 (4)
Yes	14	1 (8)	3	0 (0)	17	1 (6)
p-value		0.9				0.8
Injector						
No	27	5 (19)	2	2 (100)	29	7 (24)
Yes	16	7 (44)	3	2 (67)	19	9 (47)
p-value		0.08		0.4		0.1

Table 198: HCV antibody prevalence by region/country of birth, sex and injector status

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
Australia	34	2 (6)	7	0 (0)	41	2 (5)
Other Oceania	1	0 (0)	---	---	---	---
Asia	---	---	---	---	1	1
UK & Ireland	---	---	---	---	---	---
Other	1	0 (0)	---	---	1	0 (0)
p-value		0.9		---		0.1
Injector						
Australia	37	11 (30)	5	4 (80)	42	15 (36)
Other Oceania	1	0 (0)	---	---	1	0 (0)
Asia	---	---	---	---	---	---
UK & Ireland	1	1 (100)	---	---	1	0 (0)
Other	3	1 (33)	---	---	3	1 (33)
p-value		0.8		---		0.8

Table 199: HCV antibody prevalence by main language spoken at home by parents sex and injector status

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
Non-injector						
English speaking	34	2 (6)	7	0 (0)	41	2 (5)
Non-English speaking	2	0 (0)	---	---	2	0 (0)
p-value		0.7		---		0.7
Injector						
English speaking	42	12 (28)	4	3 (75)	46	15 (33)
Non-English speaking	---	---	1	1 (100)	1	1(100)
p-value		---		0.6		0.2

Table 200: HBV surface antigen prevalence by sex and injector status

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector	35	0 (0)	7	0 (0)	42	0 (0)
Injector	44	3 (7)	5	0 (0)	49	3 (6)
p-value		0.1		---		0.1

Table 201: HBV core antibody prevalence by sex and injector status

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector	35	3 (9)	5	0 (0)	40	3 (8)
Injector	44	11 (25)	4	2 (50)	48	13 (27)
p-value		0.06		0.07		0.02

Table 202: HBV core antibody prevalence by sexual identity, sex and injector status

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector						
Heterosexual	35	3 (9)	5	(0)	40	3 (8)
Bisexual	---	---	---	---	---	---
Homosexual	---	---	---	---	---	---
p-value		---		---		---
Injector						
Heterosexual	44	11 (25)	4	2 (50)	48	13 (27)
Bisexual	---	---	---	---	---	---
Homosexual	---	---	---	---	---	---
p-value		---		---		---

Table 203: HBV core antibody prevalence by age group, sex and injector status

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector						
< 20 years	7	0 (0)	---	---	7	0 (0)
20 – 24	7	0 (0)	1	1 (100)	8	1 (13)
25 – 29	7	1 (14)	---	---	7	1 (14)
30 + years	14	2 (14)	4	4 (100)	18	6 (33)
p-value		0.5		---		0.6
Injector						
< 20 years	4	0 (0)	---	---	4	0 (0)
20 – 24	11	1 (9)	---	---	11	1 (9)
25 – 29	9	2 (22)	2	1 (50)	11	3 (27)
30 + years	20	8 (40)	2	1 (50)	22	9 (41)
p-value		0.2		1.0		0.1

Table 204: HBV core antibody prevalence by duration of drug injection and sex

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
<3 years	9	1 (11)	---	---	9	1 (11)
3 to 5 years	5	0 (0)	---	---	5	0 (0)
6 to 10 years	13	3 (23)	1	1 (100)	14	4 (29)
10 + years	16	7 (44)	2	1 (50)	18	8 (44)
Not reported	1	0 (0)	1	0 (0)	2	0 (0)
p-value		0.2				0.2

Table 205: HBV core antibody prevalence by last drug injected and duration of drug injection

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Amphetamine	8	1 (13)	32	10 (31)	41	11 (27)
Heroin	---	---	---	---	---	---
More than one	1	0 (0)	3	1 (33)	4	1 (25)
Other/not reported		---	3	1 (33)	3	1 (33)
p-value		0.7		1.0		1.0

Table 206: HBV core antibody prevalence by frequency of injection last month and duration of drug injection

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Less than daily	5	1 (20)	22	7 (32)	27	8 (30)
Daily or more	4	0 (0)	16	5 (31)	21*	5 (24)
p-value		0.3		0.9		0.7

*Total includes those who did not report duration of drug injection

Table 207: HBV core antibody prevalence by reuse of someone else's needle and syringe last month and duration of drug injection

Reused someone else's needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
No	6	1 (17)	14	6 (43)	20	1 (35)
Yes	1	0 (0)	5	2 (40)	7	2 (29)
Not reported		---	2	1 (50)	2	1 (50)
p-value		0.7		1.0		0.9

*Total includes those who did not report duration of drug injection

Table 208: HBV core antibody prevalence by imprisonment last year and duration of drug injection

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
No	6	0 (0)	18	6 (33)	24	6 (25)
Yes	3	1 (33)	18	6 (33)	21	7 (33)
p-value		0.1		1.0		0.5

Table 209: HBV core antibody prevalence by years spent previously in prison, sex and injector status

Years spent previously in prison	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HCBV (%)
Non-injector						
No previous imprisonment	13	0 (0)	3	0 (0)	16	0 (0)
1 year or less	13	2 (15)	2	0 (0)	15	2 (13)
> 1 to 3 years	7	1 (14)	---	---	7	1 (14)
> 3 years	1	0 (0)	---	---	1	0 (0)
Not reported	1	0 (0)	---	---	1	0 (0)
p-value		0.7		---		0.6
Injector						
No previous imprisonment	15	2 (13)	1	0 (0)	16	2 (13)
1 year or less	16	4 (25)	2	1 (50)	18	5 (28)
> 1 to 3 years	5	1 (20)	1	1 (100)	6	2 (33)
> 3 years	8	4 (50)	---	---	8	4 (50)
p-value		0.3		0.4		0.3

Table 210: HBV core antibody prevalence by number of previous imprisonments, sex and injector status

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector						
No previous imprisonments	13	4 (31)	4	1 (25)	17	5 (29)
1 to 2	9	2 (22)	2	0 (0)	11	2 (18)
3 to 5	7	1 (14)	1	1 (100)	8	2 (25)
5 +	1	1 (100)	---	---	1	1 (100)
Not reported	2	0 (0)	---	---	2	0 (0)
p-value		0.4		---		0.4
Injector						
No previous imprisonments	13	2 (15)	1	0 (0)	14	2 (14)
1 to 2	8	2 (25)	1	1 (100)	9	3 (33)
3 to 5	7	5 (71)	1	1 (100)	8	6 (75)
5 +	4	3 (75)	---	---	4	3 (75)
Not reported	1	1 (100)	---	---	1	1 (100)
p-value		0.03		0.2		0.02

Table 211: Self reported hepatitis B immunisation versus serology results

Self reported number of hepatitis B vaccinations received	Serological markers of immunity*					
	Male		Female		Total	
	Nº tested	Nº immune (%)	Nº tested	Nº immune (%)	Nº tested	Nº immune (%)
Nil vaccinations received	31	5 (16)	5	2 (40)	36	7 (19)
One vaccination	2	0 (0)	---	---	2	0 (0)
Two vaccinations	9	5 (56)	---	---	9	5 (56)
Three or more vaccinations	11	6 (55)	---	---	11	6 (55)
Unsure or not reported	12	5 (42)	2	0 (0)	14	5 (36)
Total	65	21 (32)	7	2 (29)	72	23 (32)
p-value		0.04		0.3		0.08

*Surface antibody levels of $\geq$10 are considered immune. Those with serological markers of immunity from a previous HBV infection have been excluded.

Table 212: Prevalence of serological markers of HBV immunity from vaccination* by number of previous imprisonments, sex and injector status**

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° immune to HBV(%)	N° tested	N° immune to HBV(%)	N° tested	N° immune to HBV(%)
Non-injector						
No previous imprisonment	13	0 (0)	2	0 (0)	15	0 (0)
1 to 2	12	3 (25)	2	0 (0)	14	3 (21)
3 to 5	7	0 (0)	1	0 (0)	8	0 (0)
5 +	1	0 (0)	---	---	1	0 (0)
Not reported	2	0 (0)	---	---	2	0 (0)
p-value		0.2		---		0.2
Injector						
No previous imprisonment	15	2 (13)	1	0 (0)	16	2 (13)
1 to 2	9	1 (11)	2	1 (50)	11	2 (18)
3 to 5	12	5 (42)	1	1 (100)	13	6 (46)
5 +	7	3 (43)	---	---	7	3 (43)
Not reported	1	0 (0)	---	---	1	0 (0)
p-value		0.3		0.4		0.2

*Cases with HBV surface antibody levels of ten or more are considered to be immune

**HBV core antibody positive cases have been excluded

Table 213: Prevalence of serological markers of HBV immunity from vaccination* by years spent previously in prison, sex and injector status**

Years spent previously in prison	Male		Female		Total	
	N° tested	N° immune to HBV(%)	N° tested	N° immune to HBV(%)	N° tested	N° immune to HBV(%)
Non-injector						
No previous imprisonment	13	4 (31)	5	1 (20)	18	5 (28)
1 year or less	11	2 (18)	2	1 (50)	13	3 (23)
> 1 to 3 years	6	2 (33)	---	---	6	2 (33)
> 3 years	1	0 (0)	---	---	1	0 (0)
Not reported	1	0 (0)	---	---	1	0 (0)
p-value		0.8		0.4		0.9
Injector						
No previous imprisonment	13	2 (15)	1	0 (0)	14	2 (14)
1 year or less	12	4 (33)	1	1 (100)	13	5 (38)
> 1 to 3 years	4	4 (100)	1	1 (100)	5	5 (100)
> 3 years	4	3 (75)	---	---	4	3 (75)
p-value		0.01		0.2		0.01

*Cases with HBV surface antibody levels of ten or more are considered to be immune

**HBV core antibody positive cases have been excluded

Table 214: Self-reported exposure to HBV versus serology by sex and injector status

Self-report HBV	Hepatitis B serology*					
	Male		Female		Total	
	N° tested	N° with HBV(%)	N° tested	N° with HBV(%)	N° tested	N° with HBV(%)
Non-injector						
Yes	1	0 (0)	---	---	1	0 (0)
No	32	3 (9)	4	0 (0)	36	3 (8)
Not sure		0 (0)	---	---	3	0 (0)
p-value		0.9		---		0.8
Injector						
Yes	4	3 (75)	1	1 (100)	5	4 (80)
No	36	6 (17)	2	1 (50)	38	7 (18)
Not sure	4	2 (50)	1	0 (0)	5	2 (40)
p-value		0.02		0.4		0.01

*Cases positive for HBV core antibody

Table 215: HBV serology results by Indigenous status

Indigenous Status	Nº tested	Nº (%) with no evidence of immunity	Nº (%) with vaccination conferred immunity	Nº (%) immune through previous infection	Nº (%) who are HBV carriers
Non-Indigenous	58	42 (72)	10 (17)	5 (9)	1 (2)
Indigenous	36	10 (28)	16 (44)	8 (22)	2 (6)
Total	94	52 (55)	26 (27)	13 (14)	3 (3)
p-value	< 0.001	---	---	---	---

Table 216: HBV core antibody prevalence by Indigenous status, sex and injector status

Indigenous status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector						
Non-Indigenous	22	0 (0)	3	0 (0)	25	0 (0)
Indigenous	13	3 (23)	2	0 (0)	15	3 (20)
p-value		0.02		---		0.02
Injector						
Non-Indigenous	28	5 (18)	1	1 (100)	29	6 (21)
Indigenous	16	6 (37)	3	1 (33)	19	7 (37)
p-value		0.1		0.2		0.2

Table 217: HBV core antibody prevalence by region/country of birth, sex and injector status

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector						
Australia	33	3 (9)	5	0 (0)	38	3 (8)
Other Oceania	---	---	---	---	---	---
Asia	1	0 (0)	---	---	1	1 (0)
UK & Ireland	---	---	---	---	---	---
Other	1	0 (0)	---	---	1	0 (0)
p-value		0.9		---		0.9
Injector						
Australia	38	10 (26)	4	2 (50)	42	12 (29)
Other Oceania	1	1 (100)	---	---	1	1 (100)
Asia	---	---	---	---	---	---
UK & Ireland	1	0 (0)	---	---	1	0 (0)
Other	3	0 (0)	---	---	3	0 (0)
p-value		0.2		---		0.2

Table 218: HBV core antibody prevalence by main language spoken at home by parents, sex and injector status

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
Non-injector						
English speaking	33	3 (9)	5	0 (0)	38	3 (8)
Non-English speaking	2	0 (0)	---	---	2	0 (0)
p-value		0.7		---		0.7
Injector						
English speaking	43	11 (26)	3	1 (33)	46	12 (26)
Non-English speaking	---	---	1	1 (100)	1	1 (100)
p-value		---		0.2		0.1

List of tables

NATIONAL

NEW SOUTH WALES

QUEENSLAND

TASMANIA

WESTERN AUSTRALIA

REFERENCES

1. Christensen PB, Fisker N, Krarup HB, Liebert E, Jaroslavtsev N, Christensen K et al. Hepatitis B vaccination in prison with a 3-week schedule is more efficient than the standard 6-month schedule. Vaccine 2004.

2. Butler T, Levy M, Dolan K, Kaldor J. Drug use and its correlates in an Australian prisoner population. Addiction Research and Theory 2003; 11:89-101.

3. Gore S, Bird AG. Drugs in British prisons. BMJ 2000; 316:1256-1257.

4. Butler T, Spencer J, Cui J, Vickery K, Zou J, Kaldor J. Seroprevalence of markers for hepatitis B, C and G in male and female prisoners - NSW, 1996. Australian & New Zealand Journal of Public Health 1999; 23(377):384.

5. Butler TG, Dolan KA, Ferson MJ, McGuinness LM, Brown PR, Robertson PW. Hepatitis B and C in New South Wales prisons: prevalence and risk factors. Medical Journal of Australia 1997; 166:127-130.

6. Crofts N, Stewart T, Hearne P. Spread of Bloodborne viruses among Australian prison entrants. BMJ 1996; 310:285-288.

7. Christensen PB, Krarup HB, Niesters HG, Norder H, Georgsen J. Prevalence and incidence of bloodborne viral infections among Danish prisoners. Eur J Epidemiol 2000; 16:1043-1049.

8. National Centre in HIV Epidemiology and Clinical Research. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2003. 2003. National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, NSW.

9. Butler T, Kariminia A, Levy M, Kaldor J. Prisons are a risk for hepatitis C transmission (in press). Eur J Epidemiol 2004.

10. Dolan K, Wodak A. HIV transmission in a prison system in an Australian state. Medical Journal of Australia 1999; 171:14-17.

11. Hellard ME, Hocking JS, Crofts N. The prevalence and the risk behaviours associated with the transmission of hepatitis C virus in Australian correctional facilities. Epidemiol Infect 2004; 132(June):409-415.

12. MacDonald M, Zhou J. Prevalence of HIV, HCV and injecting and sexual behaviour among IDU at Needle and Syringe Programs. Australian NSP Survey National Data Report. 2002. National Centre in HIV Epidemiology and Clinical Research, University of New South Wales.

Appendix 1 – Blood Tests and Test Kits.

Human Immunodeficiency Virus (HIV)
AxSYM HIV Ag/Ab Combo Assay. ABBOTT (USA)
HIV ½ gO AxSym ABBOTT (USA)

Hepatitis B Surface-Antibody
Monolisa Anti-HBs 3.0 Enzyme Immunoassay. BIO-RAD (USA)
AxSYM HBs Enzyme Immunoassay ABBOTT (USA)

Hepatitis B (IgG & IgM) Core-Antibody[NSW]
Monolisa Anti-HBc Plus Enzyme Immunoassay. BIO-RAD (USA)
Monolisa HBc IgM Enzyme Immunoassay. BIO-RAD (USA)
AxSYM HBc Enzyme Immunoassay ABBOTT (USA)

Hepatitis B Surface-Antigen
Monolisa HbsAg Plus Enzyme Immunoassay. BIO-RAD (USA)
Monolisa HbsAg Confirmation Enzyme Immunoassay BIO-RAD (USA)
HbsAg/HbsAG Confirmatory AxSYM ABBOTT (USA)

Hepatitis B e-Antibody & e-Antigen
Monolisa Hbe (Hbe Ag-Ab detection Enzyme Immunoassay. BIO-RAD (USA)
AxSYM Hbe 2.0 AxSYM plus ABBOTT (USA)

Hepatitis C Antibody
Innotest HCV Ab IV INNOGENETICS (Belgium)
Anti-HCV IV Enzyme Immunoassay. MUREX (UK)
Monolisa Anti-HCV Enzyme Immunoassay Plus Version 2 BIO-RAD (USA)

Appendix 2 – Testing Centres.

NSW Institute of Clinical Pathology and Medical Research.

QLD Queensland Health Pathology and Scientific Services.

TAS Northern Tasmanian Pathology Service and State Reference Laboratory Microbiology Department, Royal Hobart Hospital.

WA The Western Area Centre for Pathology and Medical Research.

APPENDIX 3

National Prison Entrants' Bloodborne Virus Survey Questionnaire

[Research nurse to fill in all sections]

State ☐ **Prison** ☐

M.I.N./C.I.S./H.F.N./O.N.

☐☐☐☐☐☐☐☐

D.O.B.

D D M M Y Y Y Y

First two letters of LAST NAME ☐☐

First two letters of FIRST NAME ☐☐

1. Gender
☐ 1. Male
☐ 2. Female
☐ 3. Transgender

2. Are you Aboriginal or Torres Strait Islander?
Aboriginal ☐
Torres Strait Islander ☐
Both Aboriginal and Torres Strait Islander ☐
Neither of the above ☐

3. First time in prison?
☐ 1. Yes
☐ 2. No

4. If not first time in prison then:

4a. How many times in prison in last twelve months ☐☐

4b. How many times in prison in lifetime ☐☐

4c. During lifetime, total no. of yrs/ months spent in adult prisons ☐☐ yrs. ☐☐ mn

5. Country of birth
☐ 1. Australia
☐ 2. Other,
Please specify _____

6. Main language spoken at home by parents
☐ 1. English
☐ 2. Other -
Please specify _____

7. In the last **12 months** before coming into prison, where did you spent the most time? Complete applicable boxes.

State or territory ☐☐☐
& Suburb (post code) ☐☐☐☐
Or Suburb (spell) ☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐
Or town / remote area ☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐
Or if overseas, specify country ☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

8a. Do you have any body or ear piercing?
☐ 1. Yes ☐ 2. No

8b. Do you have any piercing **other than** an ear piercing?
☐ 1. Yes ☐ 2. No

8c. If **YES**, to 8a or 8b, were any done in the last 12 months?
☐ 1. Yes
☐ 2. No

8d. **If pierced in the last 12 months,** who did them for you? Tick all that apply.
☐ Chemist/hairdresser/ beauty salon
☐ Professional piercer/studio
☐ Tattooist / Parlour
☐ Friend
☐ Prison inmate
☐ Self
☐ Family member
☐ Other, specify
_____

8e. If pierced by friend, inmate, self or family member in the last 12 months . had anyone else used the needle before you?
☐ 1. Yes
☐ 2. No

9a. Do you have any tattoos?
☐ 1. Yes ☐ 2. No

9b. If **YES**, were any done in the **last 12 months**?
☐ 1. Yes
☐ 2. No

9c. If **tattooed in the last 12 months**, who did your tattoo/s? Tick all that apply.
☐ Parlour / professional
☐ Friend
☐ Prison Inmate
☐ Self
☐ Family member
☐ Other, specify

10. Have you **ever** injected drugs?
- ☐ 1. Yes
- ☐ 2. No → Go to question **20a**.

11. If **YES,** how old were you when you **first** injected drugs? ☐☐

12. What was the **LAST drug** you **INJECTED?**
- ☐ 1. Heroin
- ☐ 2. Heroin + Cocaine
- ☐ 3. Cocaine
- ☐ 4. Speed
- ☐ 5. Methadone
- ☐ 6. Morphine
- ☐ 7. Anabolic steroids
- ☐ 8. Other, please specify

_____

13a. How often did you inject in the **last month**?
- ☐ 1. More then 3 times most days
- ☐ 2. 2 to 3 times most days
- ☐ 3. Once a day
- ☐ 4. More than weekly, not daily
- ☐ 5. Less than weekly (1-5 days)
- ☐ 6. Not in the last month

If you **did NOT inject last month**, go to **Q. 16**.

13b. Tick all places where you injected drugs in the **last month**?
- ☐ Prison
- ☐ Own home
- ☐ Friend's home
- ☐ Dealer's home
- ☐ Street, park or beach
- ☐ Car
- ☐ Public toilet
- ☐ Commercial "shooting" room
- ☐ MSIC (KX injecting centre in Sydney)
- ☐ Squat
- ☐ Other, please specify

_____

13c. How often did you use a **NEW** sterile needle and syringe in the **last month**?
- ☐ 1. All injections
- ☐ 2. Most of the time
- ☐ 3. Half of the time
- ☐ 4. Some of the time
- ☐ 5. Not last month

13d. Tick all equipment that you used after anyone else in the **last month**?
- ☐ Spoon
- ☐ Water
- ☐ Filter
- ☐ Tourniquet
- ☐ Drug solution / mix

13e. How many **TIMES last month** did someone else inject you after injecting themselves or others.
- ☐ 1. More than 5 times
- ☐ 2. 3 to 5 times
- ☐ 3. Once or twice
- ☐ 4. None

13f. How many **TIMES last month** did you reuse a needle & syringe **after someone else** (including your sex partner) had used it (even if it was cleaned)?
- ☐ 1. More than 5 times
- ☐ 2. 3 to 5 times
- ☐ 3. Twice
- ☐ 4. Once
- ☐ 5. None – go to Q.16

13g. Within the last month, (including your sex partner how many people did you **reuse** a needle & syringe with (even if cleaned)?
- ☐ 1. More than 5 people
- ☐ 2. 3 to 5 people
- ☐ 3. 2 people
- ☐ 4. 1 person
- ☐ 5. Don't know how many

13h. Who where these people?
- ☐ 1. Regular sex partner
- ☐ 2. Casual sex partner
- ☐ 3. Close friend
- ☐ 4. Acquaintance
- ☐ 5. Other, please specify

14. How many **TIMES last month** did you get needles & syringes from a **needle & exchange**?
- ☐ 1. Daily or almost daily
- ☐ 2. A couple of times each week
- ☐ 3. Less than weekly (2 to 5 times)
- ☐ 4. Once last week
- ☐ 5. Not in the last month

15. How many **TIMES last month** did you get needles & syringes from a **chemist**?
- ☐ 1. Daily or almost daily
- ☐ 2. A couple of times each week
- ☐ 3. Less than weekly (2 to 5 times)
- ☐ 4. Once last week
- ☐ 5. Not in the last month

16.When was the **last time** you re-used a needle after someone else?

- ☐ 1. Last month
- ☐ 2. In the last 2 to 6 months
- ☐ 3. More than 6 months ago
- ☐ 4. Never

17.Where was the **last place** you re-used a needle or syringe after someone else?

- ☐ Prison
- ☐ Own home
- ☐ Friend's home
- ☐ Dealer's home
- ☐ Street, park or beach
- ☐ Car
- ☐ Public toilet
- ☐ Commercial "shooting" room
- ☐ MSIC (KX injecting centre in Sydney)
- ☐ Squat
- ☐ Other, please specify

_____

18.Have you ever participated in the yearly finger-prick survey at a needle exchange in the community

- ☐ 1. Yes
- ☐ 2. No
- ☐ 3. Don't remember

17. Have you ever been on a methadone program?

- ☐ 1. Yes, on it now
- ☐ 2. Yes, in the past
- ☐ 3. No, never

18. Have you ever been on any other program, eg naltrexone, buprenorphine or LAAM?

- ☐ 1. Yes, am on it now
- ☐ 2. Yes, in the past
- ☐ 3. No, never

19. Have you ever had any other therapies for drug use, eg detox, counselling, N.A.?

- ☐ 1. Yes
- ☐ 2. No

20.a Have you ever had hep B infection?

☐ 1. Yes ☐ 2. No ☐ 3. Not sure

20.b. If **YES**, what is your current HBV status?

1. Cleared virus ☐ 3. Chronic carrier ☐
2. Acute carrier ☐ 4. Unsure ☐

21a. Have you ever had hep B vaccination?

☐ 1. Yes ☐ 2. No ☐ 3. Not sure

21b. If **YES**, how many injections have you had?

☐ 1. One ☐ 2. Two ☐ 3. Three or more

22a.Have you been tested for HIV?

- ☐ 1. Yes, in the last year
- ☐ 2. Yes, more than a year ago
- ☐ 3. Never tested

22b.If **YES**, what was the result of your **LAST** HIV test?

- ☐ 1. Did not have HIV
- ☐ 2. I have HIV infection
- ☐ 3. Don't know result
- ☐ 4. Declined to answer

23a.Have you been tested for hepatitis C?

- ☐ 1. Yes, in the last year
- ☐ 2. Yes, more than a year ago
- ☐ 3. Never tested

23b.If **YES**, what was the result of your **LAST** hep C test?

- ☐ 1. Did not have Hep C
- ☐ 2. I have hep C
- ☐ 3. Don't know result

If you **do not have hep C**, go to Question **25**.

24a.With your last hep C test, did you test positive for

- ☐ 1. Hep C antibody and virus
- ☐ 2. Hep C antibody but no virus
- ☐ 3. Never tested for hep C virus
- ☐ 4. Don't know

24b.What year did you find out that you had hep C?

_____

24c.Have you had (or are you having) treatment for your hep C? Tick all that apply.

- ☐ 1. No treatment
- ☐ 2. Yes, Interferon
- ☐ 3. Yes, Interferon+Ribavirin
- ☐ 4. Yes, Pegasys + Ribavirin
- ☐ 5. Other, please specify

24d. If **YES**, are you having treatment for your hep C **NOW**?

- ☐ 1. No treatment
- ☐ 2. Yes, Interferon
- ☐ 3. Yes, Interferon+Ribavirin
- ☐ 4. Yes, Pegasys + Ribavirin
- ☐ 5. Other, please specify

_____

25. Sexual identity
- ☐ 1. Heterosexual
- ☐ 2. Bisexual
- ☐ 3. Gay/lesbian
- ☐ 4. Unsure

26. Did you use a condom (or dam) the **last time** you had sex?
- ☐ 1. Yes
- ☐ 2. No

27. Have you been paid for sex? In the **last month**? (Include non-cash forms of payment
- ☐ 1. Yes
- ☐ 2. No

If yes to Q27, did you use condoms (or dams) **the last time** you were paid for sex?
- ☐ 1. Yes
- ☐ 2. No

28a.How would you describe your sexual activity **last month?**

- ☐ 1. None – **end of questionnaire**
- ☐ 2. None -partner in prison **No more questions**
- ☐ 3. Casual sex only
- ☐ 4. Regular relationship
- ☐ 5. Regular and casual sex

If **SEX LAST MONTH**

28b. How many **NEW** sex partners did you **have sex with last month?** ☐☐

28c.Did you use **condoms** with your:

NEW sex partner(s) **last month**?
- ☐ 1. No
- ☐ 2. Sometimes
- ☐ 3. Every time
- ☐ 4. No new partner

CASUAL sex partner(s) **last month**?
- ☐ 1. No
- ☐ 2. Sometimes
- ☐ 3. Every time
- ☐ 4. No casual partner

REGULAR sex partner(s) **last month**?
- ☐ 1. No
- ☐ 2. Sometimes
- ☐ 3. Every time
- ☐ 4. No regular partner

28d.**If you have a regular sex partner**, how long have you been with this partner?
- ☐ 1. One month
- ☐ 2. Two to six months
- ☐ 3. Six to twelve months
- ☐ 4. More than twelve months

29. Complete the following section if positive resultsf from previous tests have been sighted in medical file and retesting is considered unnecessary.

Test	Tick if sighted	Date of test	Testing laboratory
HIV ab +ve			
HBV Sab+ve			
HBV Cab+ve			
HBV Sag +ve			
HCV ab +ve			

ISBN: 0 7347 37440

Suggested Citation:
Butler T, Boonwaat L, Hailstone S. National Prison Entrants' Bloodborne Virus Survey, 2004. Centre for Health Research in Criminal Justice & National Centre in HIV Epidemiology and Clinical Research, University of New South Wales. 2005. ISBN: 0 7347 37440.

Telephone: +61 2 8372 3000 Facsimile +61 2 9344 4151
E-mail: tony.butler@justicehealth.nsw.gov.au